"ASSOCIATION_TYPE"	"PMID"	"NUM_SENTENCE"	"ENTITY1_TEXT"	"ENTITY1_INI"	"ENTITY1_END"	"ENTITY1_TYPE"	"ENTITY2_TEXT"	"ENTITY2_INI"	"ENTITY2_END"	"ENTITY2_TYPE"	"SENTENCE"
"PA"	17897305	8	"venous thrombosis"	53	70	"Diseases & Disorders"	"oral contraceptives"	106	125	"Chemicals & Drugs"	"Body height, weight and obesity increase the risk of venous thrombosis, especially obesity in women using oral contraceptives."
"FA"	18042885	0	"Cardiovascular thromboembolic adverse effects"	0	45	"Diseases & Disorders"	"cyclooxygenase"	62	76	"Chemicals & Drugs"	"Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs."
"FA"	18042885	0	"Cardiovascular thromboembolic adverse effects"	0	45	"Diseases & Disorders"	"nonselective antiinflammatory drugs"	104	139	"Chemicals & Drugs"	"Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs."
"FA"	18037672	8	"motion sickness"	180	195	"Diseases & Disorders"	"alfentanil"	58	68	"Chemicals & Drugs"	"The frequency of PONV did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness."
"FA"	18037672	8	"motion sickness"	180	195	"Diseases & Disorders"	"propofol"	70	78	"Chemicals & Drugs"	"The frequency of PONV did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness."
"PA"	17237684	13	"dry eye"	187	194	"Diseases & Disorders"	"botulinum toxin"	41	56	"Chemicals & Drugs"	"However, decreased tear production after botulinum toxin injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary dry eye."
"PA"	17940253	1	"neurological disorders"	61	83	"Diseases & Disorders"	"Botulinum toxins"	0	16	"Chemicals & Drugs"	"Botulinum toxins are potent neurotoxins used in a variety of neurological disorders."
"PA"	17940253	3	"spasticity"	97	107	"Diseases & Disorders"	"botulinum toxin type B"	113	135	"Chemicals & Drugs"	"We describe the case of a 10-year-old boy who developed systemic weakness following treatment of spasticity with botulinum toxin type B."
"PA"	17940253	3	"systemic weakness"	56	73	"Diseases & Disorders"	"botulinum toxin type B"	113	135	"Chemicals & Drugs"	"We describe the case of a 10-year-old boy who developed systemic weakness following treatment of spasticity with botulinum toxin type B."
"FA"	17274718	2	"gingival overgrowth"	158	177	"Diseases & Disorders"	"CsA"	145	148	"Chemicals & Drugs"	"Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (CsA)-induced gingival overgrowth."
"FA"	17274718	6	"periodontitis"	128	141	"Diseases & Disorders"	"CsA"	63	66	"Chemicals & Drugs"	"ET-1 mRNA expression was significantly higher in patients with CsA-induced gingival overgrowth (P <0.001) than in patients with periodontitis and the controls."
"PA"	17274718	6	"gingival overgrowth"	75	94	"Diseases & Disorders"	"CsA"	63	66	"Chemicals & Drugs"	"ET-1 mRNA expression was significantly higher in patients with CsA-induced gingival overgrowth (P <0.001) than in patients with periodontitis and the controls."
"PA"	17274718	9	"gingival overgrowth"	107	126	"Diseases & Disorders"	"CsA"	95	98	"Chemicals & Drugs"	"These results suggest that CsA can modulate the expression of ET-1 in gingival fibroblasts and CsA-induced gingival overgrowth."
"FA"	17274718	2	"periodontitis"	91	104	"Diseases & Disorders"	"CsA"	145	148	"Chemicals & Drugs"	"Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (CsA)-induced gingival overgrowth."
"PA"	17274718	2	"gingival overgrowth"	158	177	"Diseases & Disorders"	"cyclosporin A"	130	143	"Chemicals & Drugs"	"Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (CsA)-induced gingival overgrowth."
"PA"	18640477	10	"mild asthma"	95	106	"Diseases & Disorders"	"montelukast"	27	38	"Chemicals & Drugs"	"The evidence suggests that montelukast is an effective monotherapy controller in children with mild asthma."
"FA"	18640477	0	"mild asthma"	78	89	"Diseases & Disorders"	"montelukast"	28	39	"Chemicals & Drugs"	"Review of recent results of montelukast use as a monotherapy in children with mild asthma."
"FA"	18640477	5	"mild asthma"	92	103	"Diseases & Disorders"	"montelukast"	117	128	"Chemicals & Drugs"	"This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults."
"PA"	18640477	6	"mild asthma"	235	246	"Diseases & Disorders"	"montelukast"	171	182	"Chemicals & Drugs"	"A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, leukotriene receptor antagonist, pediatric asthma, mild asthma, exercise-induced asthma, and bronchoconstriction."
"PA"	18640477	9	"asthma"	151	157	"Diseases & Disorders"	"montelukast"	105	116	"Chemicals & Drugs"	"The results from these studies, encompassing end points measuring lung function and symptoms, found that montelukast provided effective and beneficial asthma control to children aged 2 to 14 years with mild asthma."
"PA"	18640477	5	"allergic rhinitis"	213	230	"Diseases & Disorders"	"montelukast"	117	128	"Chemicals & Drugs"	"This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults."
"PA"	18953065	12	"leukoencephalopathy"	115	134	"Diseases & Disorders"	"procarbazine"	38	50	"Chemicals & Drugs"	"The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of leukoencephalopathy."
"PA"	18953065	12	"leukoencephalopathy"	115	134	"Diseases & Disorders"	"high-dose MTX"	19	32	"Chemicals & Drugs"	"The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of leukoencephalopathy."
"PA"	18953065	12	"leukoencephalopathy"	115	134	"Diseases & Disorders"	"CCNU"	55	59	"Chemicals & Drugs"	"The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of leukoencephalopathy."
"PA"	18434457	12	"anterior shoulder dislocation"	66	95	"Diseases & Disorders"	"Intra-articular injection of lidocaine"	0	38	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"PA"	18434457	12	"pain"	114	118	"Diseases & Disorders"	"intravenous meperidine"	129	151	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"PA"	18434457	12	"pain"	114	118	"Diseases & Disorders"	"diazepam"	156	164	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"PA"	18434457	12	"anterior shoulder dislocation"	66	95	"Diseases & Disorders"	"diazepam"	156	164	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"PA"	18434457	12	"anterior shoulder dislocation"	66	95	"Diseases & Disorders"	"intravenous meperidine"	129	151	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"PA"	18434457	8	"pain"	5	9	"Diseases & Disorders"	"intra-articular lidocaine"	87	112	"Chemicals & Drugs"	"Mean pain (mm) recorded before injection, before reduction, and after reduction in the intra-articular lidocaine group was 84.3 (95% confidence interval (CI) 79.8 to 88.8), 52.6 (95% CI 45.2 to 60.1), and 27.3 (95% CI 19.9 to 34.7), respectively."
"PA"	18434457	12	"pain"	114	118	"Diseases & Disorders"	"Intra-articular injection of lidocaine"	0	38	"Chemicals & Drugs"	"Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam."
"FA"	18371953	4	"glioma"	138	144	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	53	85	"Chemicals & Drugs"	"The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules on glioma cell lines."
"PA"	18371953	11	"glioma"	178	184	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	93	125	"Chemicals & Drugs"	"Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, in glioma cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells."
"PA"	18371953	0	"glioma"	96	102	"Diseases & Disorders"	"indomethacin"	26	38	"Chemicals & Drugs"	"Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study."
"PA"	18371953	7	"glioma"	193	199	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	46	78	"Chemicals & Drugs"	"The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of glioma lines."
"PA"	18371953	7	"glioma"	193	199	"Diseases & Disorders"	"solution of indomethacin"	114	138	"Chemicals & Drugs"	"The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of glioma lines."
"PA"	18371953	9	"glioma"	22	28	"Diseases & Disorders"	"indomethacin ethyl ester-loaded nanocapsules"	100	144	"Chemicals & Drugs"	"In addition, when the glioma cells were exposed to 25 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed."
"FA"	18371953	0	"glioma"	96	102	"Diseases & Disorders"	"indomethacin ethyl ester-loaded nanocapsules"	43	87	"Chemicals & Drugs"	"Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study."
"PA"	18371953	9	"glioma"	22	28	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	64	96	"Chemicals & Drugs"	"In addition, when the glioma cells were exposed to 25 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed."
"PA"	18371953	11	"glioma"	178	184	"Diseases & Disorders"	"indomethacin ethyl ester-loaded nanocapsules"	129	173	"Chemicals & Drugs"	"Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, in glioma cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells."
"PA"	18371953	12	"glioma"	37	43	"Diseases & Disorders"	"indomethacin ethyl ester-loaded nanocapsules"	140	184	"Chemicals & Drugs"	"Further investigations using in vivo glioma model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells."
"PA"	18371953	4	"glioma"	138	144	"Diseases & Disorders"	"indomethacin ethyl ester-loaded nanocapsules"	90	134	"Chemicals & Drugs"	"The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules on glioma cell lines."
"PA"	18371953	8	"glioma"	134	140	"Diseases & Disorders"	"indomethacin ethyl ester"	17	41	"Chemicals & Drugs"	"Indomethacin and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing glioma cell proliferation."
"PA"	18371953	8	"glioma"	134	140	"Diseases & Disorders"	"Indomethacin"	0	12	"Chemicals & Drugs"	"Indomethacin and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing glioma cell proliferation."
"PA"	18371953	10	"glioma"	136	142	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	27	59	"Chemicals & Drugs"	"Interestingly, 5 microM of indomethacin-loaded nanocapsules was able to cause an antiproliferative effect without promoting necrosis in glioma cells."
"PA"	18371953	12	"glioma"	37	43	"Diseases & Disorders"	"indomethacin-loaded nanocapsules"	103	135	"Chemicals & Drugs"	"Further investigations using in vivo glioma model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells."
"PA"	17483062	0	"visceral varicella-zoster infection"	84	119	"Diseases & Disorders"	"intravenous acyclovir"	137	158	"Chemicals & Drugs"	"Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir."
"PA"	17483062	1	"visceral varicella-zoster virus"	74	105	"Diseases & Disorders"	"intravenous acyclovir"	211	232	"Chemicals & Drugs"	"We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV)."
"PA"	17483062	1	"VZV) infection"	107	121	"Diseases & Disorders"	"intravenous acyclovir"	211	232	"Chemicals & Drugs"	"We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV)."
"SA"	18220495	3	"refractory childhood-onset schizophrenia"	131	171	"Diseases & Disorders"	"clozapine"	183	192	"Chemicals & Drugs"	"Available studies in the literature using clozapine in the pediatric population are summarized and the NIMH experience in treating refractory childhood-onset schizophrenia cases with clozapine is discussed."
"PA"	18220495	1	"treatment-resistant schizophrenia"	55	88	"Diseases & Disorders"	"clozapine"	21	30	"Chemicals & Drugs"	"Although the role of clozapine is well established for treatment-resistant schizophrenia, it is rarely used in pediatric populations, mainly due to its potentially serious adverse effects."
"PA"	18220495	2	"schizophrenia"	77	90	"Diseases & Disorders"	"clozapine"	41	50	"Chemicals & Drugs"	"To summarize practical aspects of use of clozapine in treating children with schizophrenia and management of associated adverse effects."
"PA"	18220495	4	"refractory schizophrenia"	150	174	"Diseases & Disorders"	"clozapine"	59	68	"Chemicals & Drugs"	"Despite a higher incidence of adverse effects in children, clozapine appears to be a uniquely beneficial second-line agent for treating children with refractory schizophrenia."
"PA"	17976209	0	"Keratoacanthoma"	0	15	"Diseases & Disorders"	"red dye of a tattoo"	37	56	"Chemicals & Drugs"	"Keratoacanthoma occurring within the red dye of a tattoo."
"FA"	18300089	7	"ocular inflammation"	155	174	"Diseases & Disorders"	"antimetabolites"	12	27	"Chemicals & Drugs"	"Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years."
"SA"	18300089	11	"fatal cancer"	159	171	"Diseases & Disorders"	"immunosuppressive drugs"	75	98	"Chemicals & Drugs"	"Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of mortality and fatal cancer."
"PA"	18300089	10	"fatal malignancy"	48	64	"Diseases & Disorders"	"antimetabolites"	120	135	"Chemicals & Drugs"	"Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents."
"FA"	18300089	7	"ocular inflammation"	155	174	"Diseases & Disorders"	"alkylating agents"	48	65	"Chemicals & Drugs"	"Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years."
"FA"	18300089	7	"ocular inflammation"	155	174	"Diseases & Disorders"	"T-cell inhibitors"	29	46	"Chemicals & Drugs"	"Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years."
"PA"	18300089	10	"fatal malignancy"	48	64	"Diseases & Disorders"	"T-cell inhibitors"	149	166	"Chemicals & Drugs"	"Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents."
"FA"	18300089	11	"ocular inflammation"	103	122	"Diseases & Disorders"	"immunosuppressive drugs"	75	98	"Chemicals & Drugs"	"Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of mortality and fatal cancer."
"FA"	18300089	7	"ocular inflammation"	155	174	"Diseases & Disorders"	"immunosuppressives"	77	95	"Chemicals & Drugs"	"Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years."
"PA"	18300089	10	"fatal malignancy"	48	64	"Diseases & Disorders"	"alkylating agents"	184	201	"Chemicals & Drugs"	"Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents."
"PA"	18923587	8	"miosis"	34	40	"Diseases & Disorders"	"Garcinia kola nut extract"	74	99	"Chemicals & Drugs"	"There were consistent significant miosis in the right eyes with instilled Garcinia kola nut extract compared to the left eyes at 15, 30 and 45 minutes (p=0.0000)."
"PA"	18342498	1	"asthma"	105	111	"Diseases & Disorders"	"ICSs"	66	70	"Chemicals & Drugs"	"There is evidence in the literature that inhaled corticosteroids (ICSs) are safe for pregnant women with asthma and their infants."
"PA"	18342498	1	"asthma"	105	111	"Diseases & Disorders"	"inhaled corticosteroids"	41	64	"Chemicals & Drugs"	"There is evidence in the literature that inhaled corticosteroids (ICSs) are safe for pregnant women with asthma and their infants."
"FA"	18452197	6	"dysplasias"	191	201	"Diseases & Disorders"	"DSS"	213	216	"Chemicals & Drugs"	"An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively)."
"FA"	18452197	6	"colonic dysplasias"	63	81	"Diseases & Disorders"	"DSS"	213	216	"Chemicals & Drugs"	"An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively)."
"FA"	18452197	0	"colitis"	138	145	"Diseases & Disorders"	"azoxymethane"	94	106	"Chemicals & Drugs"	"5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis."
"PA"	18452197	0	"colitis-associated colorectal dysplasias"	31	71	"Diseases & Disorders"	"5-aminosalicylic acid"	0	21	"Chemicals & Drugs"	"5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis."
"PA"	18452197	2	"colitis-associated neoplasia"	138	166	"Diseases & Disorders"	"dextran sulfate sodium"	101	123	"Chemicals & Drugs"	"The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia."
"SA"	18452197	9	"colitis-associated dysplasias"	72	101	"Diseases & Disorders"	"low-dose 5-ASA"	24	38	"Chemicals & Drugs"	"These data suggest that low-dose 5-ASA may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis."
"SA"	18452197	9	"colonic neoplasms"	179	196	"Diseases & Disorders"	"low-dose 5-ASA"	24	38	"Chemicals & Drugs"	"These data suggest that low-dose 5-ASA may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis."
"SA"	18452197	9	"ulcerative colitis"	214	232	"Diseases & Disorders"	"low-dose 5-ASA"	24	38	"Chemicals & Drugs"	"These data suggest that low-dose 5-ASA may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis."
"SA"	18452197	1	"colitis-associated colorectal cancer"	87	123	"Diseases & Disorders"	"5-ASA"	64	69	"Chemicals & Drugs"	"The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial."
"FA"	18452197	2	"colitis-associated neoplasia"	138	166	"Diseases & Disorders"	"azoxymethane"	82	94	"Chemicals & Drugs"	"The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia."
"FA"	18452197	7	"polypoid dysplasias"	177	196	"Diseases & Disorders"	"5-ASA"	27	32	"Chemicals & Drugs"	"Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively)."
"PA"	18452197	7	"tumor"	198	203	"Diseases & Disorders"	"5-ASA"	27	32	"Chemicals & Drugs"	"Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively)."
"PA"	18452197	6	"dysplasias"	191	201	"Diseases & Disorders"	"5-ASA"	153	158	"Chemicals & Drugs"	"An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively)."
"PA"	18452197	7	"flat dysplasias"	73	88	"Diseases & Disorders"	"5-ASA"	27	32	"Chemicals & Drugs"	"Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively)."
"FA"	18452197	2	"colitis-associated neoplasia"	138	166	"Diseases & Disorders"	"DSS"	125	128	"Chemicals & Drugs"	"The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia."
"PA"	18452197	6	"colonic dysplasias"	63	81	"Diseases & Disorders"	"5-ASA"	153	158	"Chemicals & Drugs"	"An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively)."
"PA"	17167348	0	"Spinal cord infarction"	0	22	"Diseases & Disorders"	"cocaine"	36	43	"Chemicals & Drugs"	"Spinal cord infarction secondary to cocaine use."
"PA"	17167348	8	"cerebrovascular events"	33	55	"Diseases & Disorders"	"Cocaine"	0	7	"Chemicals & Drugs"	"Cocaine abuse is associated with cerebrovascular events; spinal cord effects are rarely reported."
"PA"	17167348	11	"spinal cord infarction"	43	65	"Diseases & Disorders"	"cocaine"	19	26	"Chemicals & Drugs"	"Although uncommon, cocaine abuse can cause spinal cord infarction."
"SA"	17340045	1	"sarcoidosis"	55	66	"Diseases & Disorders"	"etanercept"	87	97	"Chemicals & Drugs"	"We report two rheumatoid arthritis patients developing sarcoidosis possibly induced by etanercept."
"FA"	17340045	9	"noninfectious granulomatous syndromes"	37	74	"Diseases & Disorders"	"etanercept"	97	107	"Chemicals & Drugs"	"Recently, there have been reports of noninfectious granulomatous syndromes in patients receiving etanercept for a variety of diseases."
"FA"	17340045	0	"sarcoidosis"	15	26	"Diseases & Disorders"	"etanercept"	30	40	"Chemicals & Drugs"	"Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients."
"FA"	17340045	0	"rheumatoid arthritis"	49	69	"Diseases & Disorders"	"etanercept"	30	40	"Chemicals & Drugs"	"Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients."
"FA"	17340045	5	"erythema nodosum"	20	36	"Diseases & Disorders"	"etanercept"	90	100	"Chemicals & Drugs"	"The other developed erythema nodosum and a plaque lesion on the right arm after 1 year of etanercept."
"SA"	18164769	4	"cancer"	65	71	"Diseases & Disorders"	"statin"	49	55	"Chemicals & Drugs"	"Furthermore, there may be a relationship between statin dose and cancer."
"FA"	17989313	0	"multiple myeloma"	173	189	"Diseases & Disorders"	"BiRD"	0	4	"Chemicals & Drugs"	"BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma."
"FA"	17989313	1	"multiple myeloma"	174	190	"Diseases & Disorders"	"BiRD"	142	146	"Chemicals & Drugs"	"This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma."
"PA"	17989313	10	"multiple myeloma"	107	123	"Diseases & Disorders"	"BiRD"	0	4	"Chemicals & Drugs"	"BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma."
"FA"	18299079	1	"endophthalmitis"	102	117	"Diseases & Disorders"	"antibiotics"	71	82	"Chemicals & Drugs"	"Recent prospective studies from Europe suggest the use of intracameral antibiotics for prophylaxis of endophthalmitis, although the studies did not make a comparison with the most common United States prophylaxis techniques."
"PA"	18299079	7	"endophthalmitis"	33	48	"Diseases & Disorders"	"antibiotics"	75	86	"Chemicals & Drugs"	"A multipronged approach to limit endophthalmitis risk is also needed, with antibiotics as only part of the strategy."
"PA"	17668247	3	"nephropathic cystinosis"	38	61	"Diseases & Disorders"	"i.v.) administration of cysteamine hydrochloride"	132	180	"Chemicals & Drugs"	"In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl)."
"PA"	18713852	12	"diarrhea"	119	127	"Diseases & Disorders"	"posaconazole"	59	71	"Chemicals & Drugs"	"The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, vomiting, and diarrhea."
"PA"	18713852	9	"oropharyngeal candidiasis"	60	85	"Diseases & Disorders"	"Posaconazole"	0	12	"Chemicals & Drugs"	"Posaconazole is noninferior to fluconazole for treatment of oropharyngeal candidiasis (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist."
"PA"	18713852	8	"aspergillosis"	105	118	"Diseases & Disorders"	"itraconazole"	183	195	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	8	"invasive fungal infections"	52	78	"Diseases & Disorders"	"itraconazole"	183	195	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	12	"nausea"	97	103	"Diseases & Disorders"	"posaconazole"	59	71	"Chemicals & Drugs"	"The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, vomiting, and diarrhea."
"PA"	18713852	12	"vomiting"	105	113	"Diseases & Disorders"	"posaconazole"	59	71	"Chemicals & Drugs"	"The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, vomiting, and diarrhea."
"PA"	18713852	8	"aspergillosis"	105	118	"Diseases & Disorders"	"posaconazole"	31	43	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	8	"invasive fungal infections"	52	78	"Diseases & Disorders"	"posaconazole"	31	43	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	12	"headache"	80	88	"Diseases & Disorders"	"posaconazole"	59	71	"Chemicals & Drugs"	"The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, vomiting, and diarrhea."
"SA"	18713852	14	"invasive fungal infection"	100	125	"Diseases & Disorders"	"posaconazole"	14	26	"Chemicals & Drugs"	"At this time, posaconazole should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies."
"SA"	18713852	14	"resistant infections"	163	183	"Diseases & Disorders"	"posaconazole"	14	26	"Chemicals & Drugs"	"At this time, posaconazole should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies."
"PA"	18713852	8	"invasive fungal infections"	52	78	"Diseases & Disorders"	"fluconazole"	167	178	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	8	"aspergillosis"	105	118	"Diseases & Disorders"	"fluconazole"	167	178	"Chemicals & Drugs"	"Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients."
"PA"	18713852	7	"aspergillosis"	131	144	"Diseases & Disorders"	"Posaconazole"	0	12	"Chemicals & Drugs"	"Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole."
"PA"	18713852	7	"invasive fungal infections"	69	95	"Diseases & Disorders"	"Posaconazole"	0	12	"Chemicals & Drugs"	"Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole."
"PA"	18713852	9	"oropharyngeal candidiasis"	60	85	"Diseases & Disorders"	"fluconazole"	31	42	"Chemicals & Drugs"	"Posaconazole is noninferior to fluconazole for treatment of oropharyngeal candidiasis (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist."
"PA"	18713852	7	"invasive fungal infections"	69	95	"Diseases & Disorders"	"fluconazole"	274	285	"Chemicals & Drugs"	"Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole."
"PA"	18713852	7	"aspergillosis"	131	144	"Diseases & Disorders"	"fluconazole"	274	285	"Chemicals & Drugs"	"Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole."
"SA"	17499360	5	"cerebellar deficits"	233	252	"Diseases & Disorders"	"succimer"	191	199	"Chemicals & Drugs"	"While some beneficial neuromotor effects of succimer therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how succimer therapy modifies lead-associated cerebellar deficits manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion."
"FA"	18395883	1	"multiple sclerosis"	65	83	"Diseases & Disorders"	"Long-term immunomodulatory drug"	0	31	"Chemicals & Drugs"	"Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (MS)."
"PA"	17484031	1	"cardiovascular diseases"	82	105	"Diseases & Disorders"	"tobacco smoke"	22	35	"Chemicals & Drugs"	"It is well known that tobacco smoke exposure is related to the risk of developing cardiovascular diseases and events."
"PA"	17634547	1	"vasomotor symptoms"	92	110	"Diseases & Disorders"	"Tibolone"	0	8	"Chemicals & Drugs"	"Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of vasomotor symptoms in postmenopausal women."
"FA"	17634547	13	"tumor"	87	92	"Diseases & Disorders"	"tibolone"	31	39	"Chemicals & Drugs"	"In ER+ breast tumors, 2.5 mg/d tibolone given for 14 days has no significant effect on tumor cell proliferation."
"FA"	17634547	13	"ER+ breast tumors"	3	20	"Diseases & Disorders"	"tibolone"	31	39	"Chemicals & Drugs"	"In ER+ breast tumors, 2.5 mg/d tibolone given for 14 days has no significant effect on tumor cell proliferation."
"FA"	17894421	1	"congenital malformations"	117	141	"Diseases & Disorders"	"BZD"	29	32	"Chemicals & Drugs"	"Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts."
"FA"	17894421	1	"orofacial clefts"	156	172	"Diseases & Disorders"	"Benzodiazepines"	12	27	"Chemicals & Drugs"	"Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts."
"FA"	17894421	1	"congenital malformations"	117	141	"Diseases & Disorders"	"Benzodiazepines"	12	27	"Chemicals & Drugs"	"Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts."
"FA"	17894421	11	"preterm birth"	58	71	"Diseases & Disorders"	"BZD"	16	19	"Chemicals & Drugs"	"Maternal use of BZD and/or HBRA may increase the risk for preterm birth and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential."
"FA"	17894421	1	"orofacial clefts"	156	172	"Diseases & Disorders"	"BZD"	29	32	"Chemicals & Drugs"	"Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts."
"NA"	19117254	12	"vascular lesions"	100	116	"Diseases & Disorders"	"etonogestrel"	141	153	"Chemicals & Drugs"	"We found no evidence of impaired control of the carbohydrate and lipid metabolism or aggravation of vascular lesions during the two years an etonogestrel implant was used by diabetic women."
"PA"	18230056	0	"infections due to Gram-positive pathogens"	55	96	"Diseases & Disorders"	"Oritavancin"	0	11	"Chemicals & Drugs"	"Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens."
"PA"	18208910	10	"long-term cognitive impairment"	196	226	"Diseases & Disorders"	"ecstasy/cannabis"	42	58	"Chemicals & Drugs"	"Our findings support that ecstasy use, or ecstasy/cannabis synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for long-term cognitive impairment owing to ecstasy consumption in the context of polydrug use."
"FA"	18208910	8	"deficits on verbal fluency"	48	74	"Diseases & Disorders"	"ecstasy"	16	23	"Chemicals & Drugs"	"After two years ecstasy users showed persistent deficits on verbal fluency, working memory and processing speed."
"FA"	18208910	7	"deficits on episodic memory"	137	164	"Diseases & Disorders"	"ecstasy"	64	71	"Chemicals & Drugs"	"When ecstasy users were classified according to lifetime use of ecstasy, the more severe users (more than 100 tablets) showed additional deficits on episodic memory."
"FA"	18586644	8	"infections"	171	181	"Diseases & Disorders"	"NaFe-EDTA"	67	76	"Chemicals & Drugs"	"No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects."
"FA"	18586644	8	"iron-deficiency anemia"	116	138	"Diseases & Disorders"	"NaFe-EDTA"	67	76	"Chemicals & Drugs"	"No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects."
"FA"	18586644	8	"iron-deficiency anemia"	116	138	"Diseases & Disorders"	"FeSO4"	49	54	"Chemicals & Drugs"	"No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects."
"FA"	18586644	8	"infections"	171	181	"Diseases & Disorders"	"FeSO4"	49	54	"Chemicals & Drugs"	"No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects."
"FA"	19135998	1	"chronic hepatitis C genotype 4"	88	118	"Diseases & Disorders"	"peginterferon"	132	145	"Chemicals & Drugs"	"Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus ribavirin."
"PA"	19135998	7	"anemia"	79	85	"Diseases & Disorders"	"ribavirin"	110	119	"Chemicals & Drugs"	"Adverse events were similar across treatment groups except for higher rates of anemia in the groups receiving ribavirin."
"PA"	19135998	1	"chronic hepatitis C genotype 4"	88	118	"Diseases & Disorders"	"ribavirin"	151	160	"Chemicals & Drugs"	"Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus ribavirin."
"FA"	18058121	1	"spontaneous abortions"	97	118	"Diseases & Disorders"	"radioisotopes of metals and halogen elements"	12	56	"Chemicals & Drugs"	"Exposure to radioisotopes of metals and halogen elements occurring in medical practice may cause spontaneous abortions."
"PA"	18058121	7	"spontaneous abortions"	130	151	"Diseases & Disorders"	"radioisotopes"	60	73	"Chemicals & Drugs"	"For exposure levels within standard recommended guidelines, radioisotopes are far more likely to play a role in the occurrence of spontaneous abortions than X-rays."
"FA"	18058121	5	"spontaneous abortions"	79	100	"Diseases & Disorders"	"radioisotopes"	17	30	"Chemicals & Drugs"	"Women exposed to radioisotopes experienced at least a threefold higher rate of spontaneous abortions than those exposed to X-ray (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01)."
"PA"	17391803	0	"advanced-stage non-small-cell lung cancer"	59	100	"Diseases & Disorders"	"docetaxel"	45	54	"Chemicals & Drugs"	"An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study."
"PA"	19026757	8	"asthma-related deaths"	50	71	"Diseases & Disorders"	"LABA"	12	16	"Chemicals & Drugs"	"Contrarily, LABA showed a significant increase in asthma-related deaths (Relative Risk=3.83; 95% CI, 1.21-12.14)."
"FA"	19026757	5	"asthma exacerbations"	22	42	"Diseases & Disorders"	"corticosteroids"	67	82	"Chemicals & Drugs"	"Primary outcomes were asthma exacerbations (AE) requiring systemic corticosteroids or hospitalization, life-threatening exacerbations and asthma-related deaths."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"high-dose cyclophosphamide"	126	152	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"adriamycin"	171	181	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"cisplatin"	270	279	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"prednisone"	296	306	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"vincristine"	198	209	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"cytarabine"	281	291	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	18303032	2	"PTCL"	95	99	"Diseases & Disorders"	"etoposide"	259	268	"Chemicals & Drugs"	"Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone."
"PA"	17541882	8	"negative symptoms"	132	149	"Diseases & Disorders"	"ziprasidone"	7	18	"Chemicals & Drugs"	"Plasma ziprasidone levels ranged from 20 ng/mL to 160 ng/mL (mean: 75.8 ng/mL) and were significantly related to the improvement in negative symptoms."
"PA"	17541882	9	"extrapyramidal symptoms"	122	145	"Diseases & Disorders"	"ziprasidone"	75	86	"Chemicals & Drugs"	"The study showed that ziprasidone was effective and tolerable, that use of ziprasidone was characterized by an absence of extrapyramidal symptoms and weight gain, and that no alterations in clinical laboratory tests occurred."
"PA"	19033289	10	"inflammation"	30	42	"Diseases & Disorders"	"bevacizumab"	54	65	"Chemicals & Drugs"	"Characteristic features of an inflammation induced by bevacizumab injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection."
"PA"	17562245	1	"high-grade non-Hodgkin lymphoma"	179	210	"Diseases & Disorders"	"prednisone"	87	97	"Chemicals & Drugs"	"Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients."
"PA"	17562245	1	"high-grade non-Hodgkin lymphoma"	179	210	"Diseases & Disorders"	"rituximab"	36	45	"Chemicals & Drugs"	"Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients."
"PA"	17562245	1	"high-grade non-Hodgkin lymphoma"	179	210	"Diseases & Disorders"	"doxorubicin"	63	74	"Chemicals & Drugs"	"Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients."
"PA"	17562245	1	"high-grade non-Hodgkin lymphoma"	179	210	"Diseases & Disorders"	"cyclophosphamide"	46	62	"Chemicals & Drugs"	"Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients."
"PA"	17562245	1	"high-grade non-Hodgkin lymphoma"	179	210	"Diseases & Disorders"	"vincristine"	75	86	"Chemicals & Drugs"	"Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients."
"PA"	18512713	9	"lung cancer"	140	151	"Diseases & Disorders"	"methotrexate"	38	50	"Chemicals & Drugs"	"Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer."
"PA"	18512713	9	"melanoma"	102	110	"Diseases & Disorders"	"methotrexate"	38	50	"Chemicals & Drugs"	"Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer."
"PA"	18512713	9	"non-Hodgkin's lymphoma"	112	134	"Diseases & Disorders"	"methotrexate"	38	50	"Chemicals & Drugs"	"Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer."
"FA"	18512713	8	"malignancy"	42	52	"Diseases & Disorders"	"methotrexate"	59	71	"Chemicals & Drugs"	"There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8)."
"PA"	18512713	8	"non-Hodgkin's lymphoma"	263	285	"Diseases & Disorders"	"methotrexate"	59	71	"Chemicals & Drugs"	"There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8)."
"PA"	18512713	8	"lung cancer"	347	358	"Diseases & Disorders"	"methotrexate"	59	71	"Chemicals & Drugs"	"There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8)."
"PA"	18512713	8	"melanoma"	206	214	"Diseases & Disorders"	"methotrexate"	59	71	"Chemicals & Drugs"	"There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8)."
"PA"	18512713	0	"rheumatoid arthritis"	51	71	"Diseases & Disorders"	"methotrexate"	94	106	"Chemicals & Drugs"	"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate."
"PA"	18512713	1	"rheumatoid arthritis"	44	64	"Diseases & Disorders"	"methotrexate"	92	104	"Chemicals & Drugs"	"To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice."
"PA"	18512713	1	"cancer"	13	19	"Diseases & Disorders"	"methotrexate"	92	104	"Chemicals & Drugs"	"To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice."
"PA"	18512713	0	"malignancies"	32	44	"Diseases & Disorders"	"methotrexate"	94	106	"Chemicals & Drugs"	"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate."
"PA"	18512713	0	"melanoma"	13	21	"Diseases & Disorders"	"methotrexate"	94	106	"Chemicals & Drugs"	"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate."
"FA"	18205897	1	"heparin-induced thrombocytopenia type II"	91	131	"Diseases & Disorders"	"Recombinant hirudin"	0	19	"Chemicals & Drugs"	"Recombinant hirudin is used as an alternative anticoagulant, particularly in patients with heparin-induced thrombocytopenia type II."
"PA"	18198174	5	"colitis"	69	76	"Diseases & Disorders"	"dextran sodium sulfate"	38	60	"Chemicals & Drugs"	"Absence of villin predisposes mice to dextran sodium sulfate-induced colitis by promoting apoptosis."
"FA"	18389682	2	"thromboembolism"	210	225	"Diseases & Disorders"	"anticoagulant"	105	118	"Chemicals & Drugs"	"Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting heparin therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and mortality."
"FA"	18389682	1	"thrombosis"	152	162	"Diseases & Disorders"	"anticoagulant"	109	122	"Chemicals & Drugs"	"Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require anticoagulant medication for prevention of thrombosis."
"PA"	18389682	2	"thromboembolism"	210	225	"Diseases & Disorders"	"heparin"	135	142	"Chemicals & Drugs"	"Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting heparin therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and mortality."
"PA"	17945482	8	"lung cancer"	213	224	"Diseases & Disorders"	"sutent"	88	94	"Chemicals & Drugs"	"Finally, in non-small cell lung cancer (NSCLC) in patients' progressing on chemotherapy sutent was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer."
"PA"	17945482	3	"metastatic renal cell carcinoma"	106	137	"Diseases & Disorders"	"sutent"	35	41	"Chemicals & Drugs"	"In several phase I/II/III studies, sutent was found to be effective as second and first line treatment in metastatic renal cell carcinoma (RCC)."
"PA"	17945482	8	"NSCLC"	40	45	"Diseases & Disorders"	"sutent"	88	94	"Chemicals & Drugs"	"Finally, in non-small cell lung cancer (NSCLC) in patients' progressing on chemotherapy sutent was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer."
"PA"	17945482	5	"GIST"	101	105	"Diseases & Disorders"	"Sutent"	0	6	"Chemicals & Drugs"	"Sutent was also effective as second line treatment in patients with gastrointestinal stromal tumors (GIST) with 8% response rate, 70% stable disease and a 20-month median survival."
"PA"	17945482	7	"breast cancer"	57	70	"Diseases & Disorders"	"sutent"	72	78	"Chemicals & Drugs"	"In addition, a phase II study in multitreated women with breast cancer, sutent demonstrated a moderate activity with 16% clinical benefit."
"PA"	18533797	1	"anemia"	171	177	"Diseases & Disorders"	"Epoetin beta"	0	12	"Chemicals & Drugs"	"Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies."
"FA"	18533797	3	"cancer"	156	162	"Diseases & Disorders"	"epoetin beta"	93	105	"Chemicals & Drugs"	"This once-weekly regimen is generally well tolerated, and studies to date have reported that epoetin beta has a neutral effect on survival of patients with cancer."
"FA"	18533797	0	"anemia"	98	104	"Diseases & Disorders"	"Epoetin beta"	0	12	"Chemicals & Drugs"	"Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia."
"PA"	18790215	5	"immunosuppression"	116	133	"Diseases & Disorders"	"mycophenolate mofetil"	56	77	"Chemicals & Drugs"	"During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression."
"PA"	18790215	5	"immunosuppression"	116	133	"Diseases & Disorders"	"tacrolimus"	28	38	"Chemicals & Drugs"	"During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression."
"PA"	18790215	5	"immunosuppression"	116	133	"Diseases & Disorders"	"methylprednisolone"	83	101	"Chemicals & Drugs"	"During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression."
"PA"	18790215	5	"immunosuppression"	116	133	"Diseases & Disorders"	"cyclosporine"	42	54	"Chemicals & Drugs"	"During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression."
"PA"	17697016	1	"anaemia"	104	111	"Diseases & Disorders"	"interferon"	61	71	"Chemicals & Drugs"	"The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia."
"PA"	17697016	6	"anaemia"	37	44	"Diseases & Disorders"	"zidovudine"	79	89	"Chemicals & Drugs"	"In multivariate analysis the risk of anaemia was significantly associated with zidovudine (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and peg-IFN (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179)."
"PA"	17697016	8	"anaemia"	47	54	"Diseases & Disorders"	"Zidovudine"	0	10	"Chemicals & Drugs"	"Zidovudine discontinuation could help to avoid anaemia associated with anti-HCV therapy."
"PA"	17697016	7	"anaemia"	12	19	"Diseases & Disorders"	"protease inhibitor"	149	167	"Chemicals & Drugs"	"The risk of anaemia was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114)."
"PA"	17697016	1	"anaemia"	104	111	"Diseases & Disorders"	"ribavirin"	77	86	"Chemicals & Drugs"	"The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia."
"PA"	18713156	7	"migraine headache"	97	114	"Diseases & Disorders"	"propranolol"	58	69	"Chemicals & Drugs"	"This study demonstrated that both low-dose topiramate and propranolol could significantly reduce migraine headache frequency, intensity, and duration."
"PA"	18713156	7	"migraine headache"	97	114	"Diseases & Disorders"	"topiramate"	43	53	"Chemicals & Drugs"	"This study demonstrated that both low-dose topiramate and propranolol could significantly reduce migraine headache frequency, intensity, and duration."
"PA"	18713156	5	"headache"	158	166	"Diseases & Disorders"	"topiramate"	14	24	"Chemicals & Drugs"	"Results - The topiramate group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001)."
"PA"	18713156	5	"migraine"	81	89	"Diseases & Disorders"	"topiramate"	14	24	"Chemicals & Drugs"	"Results - The topiramate group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001)."
"PA"	18077493	0	"hypertension"	73	85	"Diseases & Disorders"	"medium-dose glucocorticoid"	22	48	"Chemicals & Drugs"	"Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis."
"FA"	18077493	0	"rheumatoid arthritis"	103	123	"Diseases & Disorders"	"medium-dose glucocorticoid"	22	48	"Chemicals & Drugs"	"Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis."
"FA"	17547473	7	"cancer"	212	218	"Diseases & Disorders"	"amlodipine"	54	64	"Chemicals & Drugs"	"Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer."
"FA"	17547473	12	"stroke"	83	89	"Diseases & Disorders"	"Dihydropyridine calcium channel antagonists"	0	43	"Chemicals & Drugs"	"Dihydropyridine calcium channel antagonists may exert effects that protect against stroke that are independent of their blood pressure-lowering mechanism."
"PA"	17547473	16	"cardiovascular disease"	369	391	"Diseases & Disorders"	"long-acting dihydropyridine calcium channel antagonists"	197	252	"Chemicals & Drugs"	"Collectively, the cardiovascular benefit, metabolic neutrality and homogeneous blood pressure response illuminated in recent studies, and reviewed here, represent a reaffirmation of the benefit of long-acting dihydropyridine calcium channel antagonists and should serve to help reinforce the critical importance of these agents in the therapeutic armamentarium against cardiovascular disease."
"FA"	17547473	7	"coronary heart disease"	159	181	"Diseases & Disorders"	"amlodipine"	54	64	"Chemicals & Drugs"	"Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer."
"FA"	17547473	7	"gastrointestinal bleeding"	183	208	"Diseases & Disorders"	"amlodipine"	54	64	"Chemicals & Drugs"	"Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer."
"PA"	17547473	7	"cardiovascular events"	75	96	"Diseases & Disorders"	"amlodipine"	54	64	"Chemicals & Drugs"	"Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer."
"FA"	17547473	9	"hypertension"	125	137	"Diseases & Disorders"	"Dihydropyridine calcium channel antagonists"	0	43	"Chemicals & Drugs"	"Dihydropyridine calcium channel antagonists have several noteworthy attributes that merit consideration in the management of hypertension."
"PA"	17726209	5	"stomal varices secondary to portal hypertension"	68	115	"Diseases & Disorders"	"silver nitrate"	174	188	"Chemicals & Drugs"	"All three patients had recurrent admissions for stomal bleeding and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, silver nitrate, and suture ligation)."
"PA"	17726209	5	"stomal bleeding"	48	63	"Diseases & Disorders"	"silver nitrate"	174	188	"Chemicals & Drugs"	"All three patients had recurrent admissions for stomal bleeding and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, silver nitrate, and suture ligation)."
"PA"	18975369	7	"gout"	186	190	"Diseases & Disorders"	"allopurinol"	112	123	"Chemicals & Drugs"	"At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function."
"PA"	18975369	7	"hyperuricemia"	168	181	"Diseases & Disorders"	"allopurinol"	112	123	"Chemicals & Drugs"	"At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function."
"PA"	18975369	4	"impaired renal function"	62	85	"Diseases & Disorders"	"febuxostat"	99	109	"Chemicals & Drugs"	"A significantly (P < 0.05) higher percentage of subjects with impaired renal function treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10)."
"PA"	18975369	6	"gout flares"	73	84	"Diseases & Disorders"	"allopurinol"	137	148	"Chemicals & Drugs"	"The primary reasons for withdrawal were similar across groups except for gout flares, which were more frequent with febuxostat than with allopurinol."
"PA"	18975369	7	"gout"	186	190	"Diseases & Disorders"	"febuxostat"	22	32	"Chemicals & Drugs"	"At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function."
"PA"	18975369	7	"impaired renal function"	232	255	"Diseases & Disorders"	"febuxostat"	22	32	"Chemicals & Drugs"	"At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function."
"PA"	18975369	7	"hyperuricemia"	168	181	"Diseases & Disorders"	"febuxostat"	22	32	"Chemicals & Drugs"	"At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function."
"PA"	18975369	4	"impaired renal function"	62	85	"Diseases & Disorders"	"allopurinol"	256	267	"Chemicals & Drugs"	"A significantly (P < 0.05) higher percentage of subjects with impaired renal function treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10)."
"PA"	18975369	6	"gout flares"	73	84	"Diseases & Disorders"	"febuxostat"	116	126	"Chemicals & Drugs"	"The primary reasons for withdrawal were similar across groups except for gout flares, which were more frequent with febuxostat than with allopurinol."
"PA"	18975369	5	"dizziness"	130	139	"Diseases & Disorders"	"febuxostat"	166	176	"Chemicals & Drugs"	"Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and dizziness were more frequent in the febuxostat 240 mg group."
"PA"	18975369	5	"diarrhea"	117	125	"Diseases & Disorders"	"febuxostat"	166	176	"Chemicals & Drugs"	"Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and dizziness were more frequent in the febuxostat 240 mg group."
"FA"	17688650	1	"teratogenicity"	16	30	"Diseases & Disorders"	"antiepileptic drugs"	34	53	"Chemicals & Drugs"	"The established teratogenicity of antiepileptic drugs raises important issues in women of child-bearing age."
"PA"	17688650	2	"neural tube defects"	30	49	"Diseases & Disorders"	"antiepileptic drugs"	54	73	"Chemicals & Drugs"	"While the association between neural tube defects and antiepileptic drugs is well recognised, other congenital malformations are known to occur."
"PA"	17688650	2	"congenital malformations"	100	124	"Diseases & Disorders"	"antiepileptic drugs"	54	73	"Chemicals & Drugs"	"While the association between neural tube defects and antiepileptic drugs is well recognised, other congenital malformations are known to occur."
"NA"	18609261	11	"hypogonadism"	54	66	"Diseases & Disorders"	"cyclophosphamide"	83	99	"Chemicals & Drugs"	"Data of our study revealed an unexpected high rate of hypogonadism irrespective of cyclophosphamide use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation."
"PA"	18609261	11	"vasculitis"	154	164	"Diseases & Disorders"	"cyclophosphamide"	83	99	"Chemicals & Drugs"	"Data of our study revealed an unexpected high rate of hypogonadism irrespective of cyclophosphamide use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation."
"PA"	18560637	7	"autoimmune hepatitis"	56	76	"Diseases & Disorders"	"azathioprine"	39	51	"Chemicals & Drugs"	"The patient was on corticosteroids and azathioprine for autoimmune hepatitis at the time of her presentation."
"PA"	17291222	0	"Pulmonary alveolar proteinosis"	0	30	"Diseases & Disorders"	"sirolimus"	61	70	"Chemicals & Drugs"	"Pulmonary alveolar proteinosis: a rare pulmonary toxicity of sirolimus."
"PA"	17291222	10	"PAP"	0	3	"Diseases & Disorders"	"SRL"	35	38	"Chemicals & Drugs"	"PAP is a very rare complication of SRL therapy with only a few cases described."
"FA"	17291222	3	"nonproductive cough"	82	101	"Diseases & Disorders"	"SRL"	27	30	"Chemicals & Drugs"	"Two years after initiating SRL, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and low-grade fever of 1 month duration."
"FA"	17291222	3	"chest pain"	103	113	"Diseases & Disorders"	"SRL"	27	30	"Chemicals & Drugs"	"Two years after initiating SRL, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and low-grade fever of 1 month duration."
"FA"	19100448	9	"leucoencephalopathy"	22	41	"Diseases & Disorders"	"SRL"	82	85	"Chemicals & Drugs"	"The only patient with leucoencephalopathy showed improved neurologic status after SRL conversion."
"PA"	19100448	10	"GI side effects"	41	56	"Diseases & Disorders"	"MMF"	60	63	"Chemicals & Drugs"	"All patients converted to SRL because of GI side effects of MMF showed improvements, and none of those converted because of hyperglycemia experienced improvement."
"PA"	19100448	12	"severe diarrhea"	191	206	"Diseases & Disorders"	"MMF"	214	217	"Chemicals & Drugs"	"We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to MMF."
"FA"	19100448	4	"gastrointestinal"	201	217	"Diseases & Disorders"	"MMF"	262	265	"Chemicals & Drugs"	"The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%)."
"FA"	19100448	4	"gastrointestinal"	201	217	"Diseases & Disorders"	"mycophenolate mofetil"	239	260	"Chemicals & Drugs"	"The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%)."
"PA"	16944312	10	"hematological side effects"	141	167	"Diseases & Disorders"	"oxcarbazepine"	10	23	"Chemicals & Drugs"	"Moreover, oxcarbazepine can be a valid choice when long-term therapy is required because of the low interaction with other drugs and the low hematological side effects."
"FA"	16944312	9	"perioperative seizures"	118	140	"Diseases & Disorders"	"antiepileptic agents"	76	96	"Chemicals & Drugs"	"Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors."
"PA"	16944312	9	"perioperative seizures"	118	140	"Diseases & Disorders"	"oxcarbazepine"	21	34	"Chemicals & Drugs"	"Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors."
"FA"	16944312	3	"perioperative seizures"	94	116	"Diseases & Disorders"	"antiepileptic agents"	51	71	"Chemicals & Drugs"	"Furthermore, the efficacy of the new generation of antiepileptic agents in the prophylaxis of perioperative seizures has not been assessed so far."
"SA"	17244684	1	"GVHD"	127	131	"Diseases & Disorders"	"oral beclomethasone dipropionate"	30	62	"Chemicals & Drugs"	"We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea."
"FA"	17244684	1	"gastrointestinal graft-versus-host disease"	83	125	"Diseases & Disorders"	"BDP"	64	67	"Chemicals & Drugs"	"We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea."
"PA"	17244684	9	"relapses of gastrointestinal GVHD"	18	51	"Diseases & Disorders"	"prednisone"	74	84	"Chemicals & Drugs"	"Oral BDP prevents relapses of gastrointestinal GVHD following tapering of prednisone; survival is statistically significantly better among patients receiving BDP."
"PA"	17244684	9	"relapses of gastrointestinal GVHD"	18	51	"Diseases & Disorders"	"BDP"	158	161	"Chemicals & Drugs"	"Oral BDP prevents relapses of gastrointestinal GVHD following tapering of prednisone; survival is statistically significantly better among patients receiving BDP."
"PA"	18398094	12	"edema"	28	33	"Diseases & Disorders"	"TAC"	121	124	"Chemicals & Drugs"	"Grade 3 or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles."
"PA"	18398094	12	"leukopenia"	13	23	"Diseases & Disorders"	"TAC"	121	124	"Chemicals & Drugs"	"Grade 3 or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles."
"PA"	17938326	0	"ABCG2"	71	76	"Genes & Molecular Sequences"	"doxorubicin"	43	54	"Chemicals & Drugs"	"Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines."
"PA"	17938326	5	"EGFR"	16	20	"Genes & Molecular Sequences"	"gefitinib"	31	40	"Chemicals & Drugs"	"Inactivation of EGFR kinase by gefitinib was analyzed by Western blot analysis and immunofluorescence."
"PA"	17938326	0	"ABCG2"	71	76	"Genes & Molecular Sequences"	"Gefitinib"	0	9	"Chemicals & Drugs"	"Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines."
"PA"	17938326	2	"ABCG2 drug transporter"	161	183	"Genes & Molecular Sequences"	"doxorubicin"	140	151	"Chemicals & Drugs"	"Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, doxorubicin, via the ABCG2 drug transporter in the presence or absence of gefitinib."
"PA"	17938326	12	"EGFR"	20	24	"Genes & Molecular Sequences"	"gefitinib"	35	44	"Chemicals & Drugs"	"Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin."
"PA"	17938326	8	"ABCG2 drug transporter"	80	102	"Genes & Molecular Sequences"	"doxorubicin"	173	184	"Chemicals & Drugs"	"Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines."
"PA"	17938326	6	"ABCG2"	128	133	"Genes & Molecular Sequences"	"doxorubicin"	172	183	"Chemicals & Drugs"	"A terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay was performed to demonstrate ABCG2-mediated apoptosis in the presence of doxorubicin."
"PA"	17938326	9	"ABCG2"	126	131	"Genes & Molecular Sequences"	"doxorubicin"	93	104	"Chemicals & Drugs"	"Both ARO and WRO demonstrated differential ABCG2 expression, whereas both were sensitized to doxorubicin-induced apoptosis on ABCG2 knockdown with short interfering RNA."
"PA"	17938326	12	"EGFR"	20	24	"Genes & Molecular Sequences"	"doxorubicin"	173	184	"Chemicals & Drugs"	"Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin."
"PA"	17938326	8	"EGFR"	14	18	"Genes & Molecular Sequences"	"doxorubicin"	173	184	"Chemicals & Drugs"	"Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines."
"PA"	17938326	8	"ABCG2 drug transporter"	80	102	"Genes & Molecular Sequences"	"gefitinib"	38	47	"Chemicals & Drugs"	"Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines."
"SA"	17938326	13	"ABCG2"	18	23	"Genes & Molecular Sequences"	"doxorubicin"	67	78	"Chemicals & Drugs"	"The expression of ABCG2 may explain in part the ineffectiveness of doxorubicin as a single modality treatment for anaplastic thyroid cancer or for treatment of metastatic follicular thyroid cancer."
"PA"	17938326	8	"EGFR"	14	18	"Genes & Molecular Sequences"	"gefitinib"	38	47	"Chemicals & Drugs"	"Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines."
"PA"	17395790	3	"oxytocin"	151	159	"Genes & Molecular Sequences"	"GSK221149A"	0	10	"Chemicals & Drugs"	"GSK221149A had similar affinity (K(i) = 4.1 nM) and selectivity for native oxytocin receptors from rat and produced a functional, competitive block of oxytocin-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18."
"PA"	17395790	5	"oxytocin"	72	80	"Genes & Molecular Sequences"	"GSK221149A"	23	33	"Chemicals & Drugs"	"Oral administration of GSK221149A (5 mg/kg) was effective in inhibiting oxytocin-induced uterine contractions after single and multiple (4-day) dosing."
"PA"	17395790	4	"oxytocin"	79	87	"Genes & Molecular Sequences"	"GSK221149A"	30	40	"Chemicals & Drugs"	"Intravenous administration of GSK221149A produced a dose-dependent decrease in oxytocin-induced uterine contractions in anesthetized rats with an ID(50) = 0.27 +/- 0.60 mg/kg (corresponding plasma concentrations were 88 ng/ml)."
"PA"	18445086	2	"PML/RARalpha"	0	12	"Genes & Molecular Sequences"	"ATRA"	62	66	"Chemicals & Drugs"	"PML/RARalpha is directly targeted by all-trans-retinoic acid (ATRA), which degrades the oncoprotein and induces complete remission of malignancies."
"PA"	18445086	7	"PML/RARalpha"	63	75	"Genes & Molecular Sequences"	"ATRA"	0	4	"Chemicals & Drugs"	"ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with MEK inhibitors."
"PA"	18426370	1	"K65R mutation"	139	152	"SNP & Sequence variations"	"tenofovir"	302	311	"Chemicals & Drugs"	"Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use."
"PA"	18610736	6	"ATP7B"	34	39	"Genes & Molecular Sequences"	"copper ions"	78	89	"Chemicals & Drugs"	"One among the 17 genes studied is ATP7B which is involved in the transport of copper ions across the cell membrane into the cell."
"FA"	17875725	0	"Topoisomerase IIbeta"	0	20	"Genes & Molecular Sequences"	"dexrazoxane"	117	128	"Chemicals & Drugs"	"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane."
"FA"	17875725	0	"Topoisomerase IIbeta"	0	20	"Genes & Molecular Sequences"	"doxorubicin"	72	83	"Chemicals & Drugs"	"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane."
"PA"	17875725	7	"Top2beta"	120	128	"Genes & Molecular Sequences"	"doxorubicin"	164	175	"Chemicals & Drugs"	"Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta, which paralleled the reduction of doxorubicin-induced DNA damage."
"FA"	17875725	6	"topoisomerase IIbeta"	264	284	"Genes & Molecular Sequences"	"MG132"	107	112	"Chemicals & Drugs"	"Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta)."
"PA"	17875725	6	"Top2beta"	286	294	"Genes & Molecular Sequences"	"Doxorubicin"	0	11	"Chemicals & Drugs"	"Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta)."
"FA"	17875725	6	"topoisomerase IIbeta"	264	284	"Genes & Molecular Sequences"	"Doxorubicin"	0	11	"Chemicals & Drugs"	"Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta)."
"PA"	17875725	8	"Top2beta"	152	160	"Genes & Molecular Sequences"	"dexrazoxane"	35	46	"Chemicals & Drugs"	"Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity."
"PA"	17875725	7	"Top2beta"	120	128	"Genes & Molecular Sequences"	"dexrazoxane"	74	85	"Chemicals & Drugs"	"Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta, which paralleled the reduction of doxorubicin-induced DNA damage."
"SA"	17875725	8	"Top2beta"	152	160	"Genes & Molecular Sequences"	"doxorubicin"	164	175	"Chemicals & Drugs"	"Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity."
"PA"	17875725	9	"Top2beta"	43	51	"Genes & Molecular Sequences"	"doxorubicin"	148	159	"Chemicals & Drugs"	"The specific involvement of proteasome and Top2beta in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks."
"PA"	17875725	6	"Top2beta"	286	294	"Genes & Molecular Sequences"	"bortezomib"	92	102	"Chemicals & Drugs"	"Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta)."
"FA"	17875725	6	"topoisomerase IIbeta"	264	284	"Genes & Molecular Sequences"	"bortezomib"	92	102	"Chemicals & Drugs"	"Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta)."
"FA"	19056662	3	"PMCA1b"	214	220	"Genes & Molecular Sequences"	"FOS"	32	35	"Chemicals & Drugs"	"After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b)."
"PA"	19056662	3	"TRPV6"	152	157	"Genes & Molecular Sequences"	"FOS"	32	35	"Chemicals & Drugs"	"After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b)."
"SA"	19056662	10	"TRPV6"	66	71	"Genes & Molecular Sequences"	"FOS"	176	179	"Chemicals & Drugs"	"We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats."
"PA"	19056662	4	"calbindin-D9k"	47	60	"Genes & Molecular Sequences"	"FOS"	4	7	"Chemicals & Drugs"	"The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression."
"FA"	19056662	4	"PMCA1b"	80	86	"Genes & Molecular Sequences"	"FOS"	4	7	"Chemicals & Drugs"	"The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression."
"PA"	19056662	4	"TRPV6"	37	42	"Genes & Molecular Sequences"	"FOS"	4	7	"Chemicals & Drugs"	"The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression."
"FA"	19056662	3	"plasma membrane calcium-ATPase 1b"	179	212	"Genes & Molecular Sequences"	"FOS"	32	35	"Chemicals & Drugs"	"After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b)."
"PA"	19056662	3	"calbindin-D9k"	160	173	"Genes & Molecular Sequences"	"FOS"	32	35	"Chemicals & Drugs"	"After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b)."
"PA"	19056662	9	"TRPV6"	246	251	"Genes & Molecular Sequences"	"FOS"	192	195	"Chemicals & Drugs"	"These results suggest that FOS increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6."
"FA"	17402796	1	"tumor necrosis factor"	108	129	"Genes & Molecular Sequences"	"Adalimumab"	0	10	"Chemicals & Drugs"	"Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF)."
"PA"	17402796	1	"TNF"	131	134	"Genes & Molecular Sequences"	"Adalimumab"	0	10	"Chemicals & Drugs"	"Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF)."
"PA"	18602931	0	"P2X7 receptors"	136	150	"Genes & Molecular Sequences"	"[3H]A-804598"	0	12	"Chemicals & Drugs"	"[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors."
"PA"	18602931	4	"P2X7 receptors"	238	252	"Genes & Molecular Sequences"	"A-804598"	56	64	"Chemicals & Drugs"	"While several species selective P2X7 antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors."
"FA"	18602931	9	"P2X antagonists"	32	47	"Genes & Molecular Sequences"	"[3H]A-804598"	59	71	"Chemicals & Drugs"	"The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05)."
"FA"	18602931	9	"P2X7 receptors"	144	158	"Genes & Molecular Sequences"	"[3H]A-804598"	59	71	"Chemicals & Drugs"	"The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05)."
"FA"	18602931	5	"P2X7 receptors"	148	162	"Genes & Molecular Sequences"	"A-804598"	0	8	"Chemicals & Drugs"	"A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors."
"PA"	18602931	5	"IL-1beta"	61	69	"Genes & Molecular Sequences"	"A-804598"	0	8	"Chemicals & Drugs"	"A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors."
"PA"	18602931	10	"P2X7 receptors"	224	238	"Genes & Molecular Sequences"	"A-804598"	28	36	"Chemicals & Drugs"	"These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian P2X7 receptors described to date and [3H]A-804598 is a high affinity antagonist radioligand that specifically labels rat P2X7 receptors."
"PA"	17293381	7	"CYP3A"	40	45	"Genes & Molecular Sequences"	"MA"	0	2	"Chemicals & Drugs"	"MA and MD were reversible inhibitors of CYP3A with competitive Ki values of 2.7 and 0.2 microM, respectively."
"FA"	17293381	5	"CYP3A"	22	27	"Genes & Molecular Sequences"	"MD"	0	2	"Chemicals & Drugs"	"MD did not inactivate CYP3A."
"PA"	17293381	0	"CYP3A"	82	87	"Genes & Molecular Sequences"	"diltiazem"	41	50	"Chemicals & Drugs"	"Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A."
"PA"	17293381	2	"CYP3A"	99	104	"Genes & Molecular Sequences"	"diltiazem"	74	83	"Chemicals & Drugs"	"We previously reported that microsomal inactivation kinetic parameters of diltiazem underpredicted CYP3A inactivation in hepatocytes."
"PA"	17293381	6	"CYP3A"	114	119	"Genes & Molecular Sequences"	"diltiazem"	215	224	"Chemicals & Drugs"	"Inactivation of CYP3A by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent."
"PA"	17293381	6	"CYP3A"	114	119	"Genes & Molecular Sequences"	"MA"	263	265	"Chemicals & Drugs"	"Inactivation of CYP3A by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent."
"PA"	17293381	10	"CYP3A"	114	119	"Genes & Molecular Sequences"	"MA"	49	51	"Chemicals & Drugs"	"In summary, time-dependent CYP3A inactivation by MA seems to be the major contributor responsible for the loss of CYP3A in human liver microsomes and human hepatocytes incubated with diltiazem."
"PA"	17293381	8	"CYP3A"	78	83	"Genes & Molecular Sequences"	"MD"	133	135	"Chemicals & Drugs"	"In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations."
"PA"	17293381	8	"CYP3A"	78	83	"Genes & Molecular Sequences"	"diltiazem"	185	194	"Chemicals & Drugs"	"In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations."
"PA"	17293381	4	"CYP3A"	78	83	"Genes & Molecular Sequences"	"diltiazem"	170	179	"Chemicals & Drugs"	"In human liver microsomes, MA was a more potent time-dependent inactivator of CYP3A than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml."
"FA"	17293381	8	"CYP3A"	78	83	"Genes & Molecular Sequences"	"MA"	146	148	"Chemicals & Drugs"	"In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations."
"PA"	17293381	4	"CYP3A"	78	83	"Genes & Molecular Sequences"	"MA"	27	29	"Chemicals & Drugs"	"In human liver microsomes, MA was a more potent time-dependent inactivator of CYP3A than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml."
"PA"	17293381	7	"CYP3A"	40	45	"Genes & Molecular Sequences"	"MD"	7	9	"Chemicals & Drugs"	"MA and MD were reversible inhibitors of CYP3A with competitive Ki values of 2.7 and 0.2 microM, respectively."
"FA"	18591256	9	"Bcr-Abl"	3	10	"Genes & Molecular Sequences"	"Gleevec"	106	113	"Chemicals & Drugs"	"In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (Gleevec) resistance."
"PA"	18591256	9	"Hsp90beta"	65	74	"Genes & Molecular Sequences"	"Gleevec"	106	113	"Chemicals & Drugs"	"In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (Gleevec) resistance."
"FA"	17626206	8	"TRPV1 channels"	70	84	"Genes & Molecular Sequences"	"AMG0347"	159	166	"Chemicals & Drugs"	"We then established that localized intra-abdominal desensitization of TRPV1 channels with intraperitoneal resiniferatoxin blocks the T(b) response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests."
"PA"	17626206	4	"TRPV1"	192	197	"Genes & Molecular Sequences"	"AMG0347"	181	188	"Chemicals & Drugs"	"We then found that this drug is the most potent TRPV1 antagonist known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is TRPV1 dependent."
"PA"	17626206	6	"TRPV1"	214	219	"Genes & Molecular Sequences"	"AMG0347"	154	161	"Chemicals & Drugs"	"The magnitude of the hyperthermic response depended on neither T(b) nor tail-skin temperature at the time of AMG0347 administration, thus indicating that AMG0347-induced hyperthermia results from blockade of tonic TRPV1 activation by nonthermal factors."
"PA"	17276892	0	"p38"	157	160	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways."
"PA"	17276892	0	"ERK"	162	165	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways."
"PA"	17276892	0	"nuclear factor-kappaB"	170	191	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways."
"PA"	17276892	6	"ICAM-1"	169	175	"Genes & Molecular Sequences"	"paeonol"	25	32	"Chemicals & Drugs"	"The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production."
"SA"	17276892	6	"p38"	86	89	"Genes & Molecular Sequences"	"paeonol"	25	32	"Chemicals & Drugs"	"The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production."
"PA"	17276892	0	"intercellular adhesion molecule-1"	19	52	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways."
"SA"	17276892	6	"NF-kappaB"	99	108	"Genes & Molecular Sequences"	"paeonol"	25	32	"Chemicals & Drugs"	"The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production."
"FA"	17276892	6	"TNF-alpha"	151	160	"Genes & Molecular Sequences"	"paeonol"	25	32	"Chemicals & Drugs"	"The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production."
"PA"	17276892	3	"p65"	117	120	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"PA"	17276892	3	"IkappaBalpha"	210	222	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"PA"	17276892	3	"inhibitory factor kappaBalpha"	179	208	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"FA"	17276892	0	"tumor necrosis factor-alpha"	67	94	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways."
"PA"	17276892	5	"TNF-alpha"	210	219	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol inhibited U937 monocyte adhesion to HUVECs stimulated by TNF-alpha, suggesting that it may inhibit the binding of monocytes to endothelium by regulating the production of critical adhesion molecules by TNF-alpha."
"SA"	17276892	2	"ICAM-1"	64	70	"Genes & Molecular Sequences"	"paeonol"	158	165	"Chemicals & Drugs"	"We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs)."
"PA"	17276892	3	"ICAM-1"	62	68	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"PA"	17276892	3	"nuclear factor-kappaB"	83	104	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"PA"	17276892	3	"NF-kappaB"	106	115	"Genes & Molecular Sequences"	"Paeonol"	0	7	"Chemicals & Drugs"	"Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha)."
"SA"	17276892	6	"ERK"	91	94	"Genes & Molecular Sequences"	"paeonol"	25	32	"Chemicals & Drugs"	"The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production."
"FA"	17967141	3	"HDL3"	154	158	"Genes & Molecular Sequences"	"estradiol"	131	140	"Chemicals & Drugs"	"Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from LDL and HDL3."
"FA"	17967141	0	"LDL"	131	134	"Genes & Molecular Sequences"	"estradiol"	116	125	"Chemicals & Drugs"	"Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3."
"FA"	17967141	0	"Scavenger receptor of class B"	0	29	"Genes & Molecular Sequences"	"estradiol"	116	125	"Chemicals & Drugs"	"Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3."
"FA"	17967141	3	"scavenger receptors"	47	66	"Genes & Molecular Sequences"	"estradiol"	131	140	"Chemicals & Drugs"	"Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from LDL and HDL3."
"FA"	17967141	0	"HDL3"	139	143	"Genes & Molecular Sequences"	"estradiol"	116	125	"Chemicals & Drugs"	"Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3."
"FA"	17967141	3	"LDL"	146	149	"Genes & Molecular Sequences"	"estradiol"	131	140	"Chemicals & Drugs"	"Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from LDL and HDL3."
"FA"	17967141	13	"HDL3"	143	147	"Genes & Molecular Sequences"	"estradiol"	82	91	"Chemicals & Drugs"	"Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors."
"FA"	17967141	13	"LDL"	135	138	"Genes & Molecular Sequences"	"estradiol"	82	91	"Chemicals & Drugs"	"Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors."
"FA"	17967141	12	"LDL"	30	33	"Genes & Molecular Sequences"	"estradiol"	9	18	"Chemicals & Drugs"	"Finally, estradiol carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors."
"FA"	17967141	12	"HDL3"	38	42	"Genes & Molecular Sequences"	"estradiol"	9	18	"Chemicals & Drugs"	"Finally, estradiol carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors."
"FA"	17967141	12	"SR-B receptors"	110	124	"Genes & Molecular Sequences"	"estradiol"	9	18	"Chemicals & Drugs"	"Finally, estradiol carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors."
"FA"	17967141	13	"SR-B receptors"	151	165	"Genes & Molecular Sequences"	"estradiol"	82	91	"Chemicals & Drugs"	"Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors."
"PA"	18026124	3	"CB1"	108	111	"Genes & Molecular Sequences"	"endocannabinoids"	17	33	"Chemicals & Drugs"	"On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid CB1/CB2 receptor-dependent and -independent mechanisms."
"FA"	18026124	3	"CB2"	112	115	"Genes & Molecular Sequences"	"endocannabinoids"	17	33	"Chemicals & Drugs"	"On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid CB1/CB2 receptor-dependent and -independent mechanisms."
"PA"	18026124	5	"CB1"	85	88	"Genes & Molecular Sequences"	"synthetic CB1 receptor agonists"	23	54	"Chemicals & Drugs"	"Previous studies using synthetic CB1 receptor agonists or knockout mice demonstrated CB1 receptor-dependent protection against cerebral I/R injury in various animal models."
"FA"	18026124	8	"CB receptors"	65	77	"Genes & Molecular Sequences"	"CB2 receptor agonists"	262	283	"Chemicals & Drugs"	"This review is aimed to discuss the role of endocannabinoids and CB receptors in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage."
"PA"	18026124	7	"CB2"	123	126	"Genes & Molecular Sequences"	"CB2 receptor agonists"	41	62	"Chemicals & Drugs"	"Excitedly, emerging studies using potent CB2 receptor agonists and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage."
"FA"	17620431	2	"VEGF"	237	241	"Genes & Molecular Sequences"	"pazopanib"	188	197	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"FA"	17620431	2	"VEGF) receptors"	94	109	"Genes & Molecular Sequences"	"pazopanib"	188	197	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"c-Kit tyrosine kinases"	164	186	"Genes & Molecular Sequences"	"pazopanib"	188	197	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"platelet-derived growth factor receptor"	119	158	"Genes & Molecular Sequences"	"pazopanib"	188	197	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"VEGFR"	111	116	"Genes & Molecular Sequences"	"pazopanib"	188	197	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"FA"	17620431	2	"VEGF"	237	241	"Genes & Molecular Sequences"	"GW786034"	199	207	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"VEGFR"	111	116	"Genes & Molecular Sequences"	"GW786034"	199	207	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"platelet-derived growth factor receptor"	119	158	"Genes & Molecular Sequences"	"GW786034"	199	207	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"PA"	17620431	2	"c-Kit tyrosine kinases"	164	186	"Genes & Molecular Sequences"	"GW786034"	199	207	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"FA"	17620431	2	"VEGF) receptors"	94	109	"Genes & Molecular Sequences"	"GW786034"	199	207	"Chemicals & Drugs"	"We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation."
"FA"	17701832	5	"CYP3A4"	82	88	"Genes & Molecular Sequences"	"5HT3 antagonists"	34	50	"Chemicals & Drugs"	"The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by CYP3A4 (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity."
"FA"	17701832	5	"CYP1A2"	116	122	"Genes & Molecular Sequences"	"5HT3 antagonists"	34	50	"Chemicals & Drugs"	"The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by CYP3A4 (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity."
"FA"	18573490	0	"interleukin-1beta"	138	155	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	6	26	"Chemicals & Drugs"	"Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages."
"FA"	18573490	4	"IkappaB) kinase beta"	200	220	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	23	43	"Chemicals & Drugs"	"In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM."
"FA"	18573490	4	"IKKbeta"	222	229	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	23	43	"Chemicals & Drugs"	"In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM."
"PA"	18573490	0	"inhibitory kappaB"	88	105	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	6	26	"Chemicals & Drugs"	"Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages."
"PA"	18573490	6	"IKKbeta"	152	159	"Genes & Molecular Sequences"	"LYR-71"	13	19	"Chemicals & Drugs"	"Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity."
"PA"	18573490	6	"IL-1beta"	169	177	"Genes & Molecular Sequences"	"LYR-71"	13	19	"Chemicals & Drugs"	"Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity."
"FA"	18573490	4	"NF-kappaB"	258	267	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	23	43	"Chemicals & Drugs"	"In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM."
"PA"	18573490	5	"NF-kappaB"	223	232	"Genes & Molecular Sequences"	"LYR-71"	0	6	"Chemicals & Drugs"	"LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB."
"PA"	18573490	7	"NF-kappaB"	73	82	"Genes & Molecular Sequences"	"LYR-71"	16	22	"Chemicals & Drugs"	"Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level."
"PA"	18573490	7	"IKKbeta"	53	60	"Genes & Molecular Sequences"	"LYR-71"	16	22	"Chemicals & Drugs"	"Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level."
"PA"	18573490	5	"IKKbeta"	17	24	"Genes & Molecular Sequences"	"LYR-71"	0	6	"Chemicals & Drugs"	"LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB."
"PA"	18573490	5	"IkappaBalpha"	157	169	"Genes & Molecular Sequences"	"LYR-71"	0	6	"Chemicals & Drugs"	"LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB."
"SA"	18573490	7	"inflammatory cytokines"	212	234	"Genes & Molecular Sequences"	"LYR-71"	16	22	"Chemicals & Drugs"	"Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level."
"FA"	18573490	0	"nuclear factor-kappaB"	45	66	"Genes & Molecular Sequences"	"iminobenzoxathiolone"	6	26	"Chemicals & Drugs"	"Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages."
"PA"	17502872	2	"TNF"	93	96	"Genes & Molecular Sequences"	"infliximab"	220	230	"Chemicals & Drugs"	"To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab)."
"PA"	19024103	8	"JNK"	83	86	"Genes & Molecular Sequences"	"F90"	145	148	"Chemicals & Drugs"	"Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro."
"PA"	19024103	8	"P38"	91	94	"Genes & Molecular Sequences"	"F90"	145	148	"Chemicals & Drugs"	"Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro."
"PA"	19024103	8	"EGFR"	19	23	"Genes & Molecular Sequences"	"F90"	145	148	"Chemicals & Drugs"	"Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro."
"PA"	19024103	8	"ERK1"	77	81	"Genes & Molecular Sequences"	"F90"	145	148	"Chemicals & Drugs"	"Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro."
"PA"	18544460	6	"VEGF"	92	96	"Genes & Molecular Sequences"	"bevacizumab"	62	73	"Chemicals & Drugs"	"Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer."
"PA"	18544460	6	"EGFR"	52	56	"Genes & Molecular Sequences"	"cetuximab"	27	36	"Chemicals & Drugs"	"Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer."
"PA"	17511782	4	"EGFR"	151	155	"Genes & Molecular Sequences"	"5-fluorouracil"	101	115	"Chemicals & Drugs"	"Using these methods, we show that EGFR kinase inhibitors sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity."
"PA"	17599377	8	"CYP1A1"	80	86	"Genes & Molecular Sequences"	"TCDD"	90	94	"Chemicals & Drugs"	"In cells grown under hypoxia for 6 h, BRCA1 was not decreased, but induction of CYP1A1 by TCDD was significantly decreased."
"PA"	17599377	2	"CYP1A1"	66	72	"Genes & Molecular Sequences"	"TCDD"	52	56	"Chemicals & Drugs"	"Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression."
"PA"	17599377	9	"CYP1A1"	105	111	"Genes & Molecular Sequences"	"TCDD"	32	36	"Chemicals & Drugs"	"Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia."
"PA"	17599377	9	"CYP1A1"	105	111	"Genes & Molecular Sequences"	"cycloheximide"	74	87	"Chemicals & Drugs"	"Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia."
"PA"	17599377	2	"CYP1A1"	66	72	"Genes & Molecular Sequences"	"2,3,7,8-tetrachlorodibenzo-p-dioxin"	15	50	"Chemicals & Drugs"	"Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression."
"PA"	17599377	3	"AhR"	55	58	"Genes & Molecular Sequences"	"TCDD"	81	85	"Chemicals & Drugs"	"In ZR-75 cells grown under hypoxia, induction of these AhR-mediated responses by TCDD was significantly inhibited."
"PA"	17345086	3	"P-gp"	82	86	"Genes & Molecular Sequences"	"flavonoids"	59	69	"Chemicals & Drugs"	"Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, P-gp-, and MRP1-mediated drug resistance."
"PA"	17345086	3	"MRP1"	93	97	"Genes & Molecular Sequences"	"flavonoids"	59	69	"Chemicals & Drugs"	"Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, P-gp-, and MRP1-mediated drug resistance."
"PA"	17345086	2	"BCRP"	49	53	"Genes & Molecular Sequences"	"flavonoids"	33	43	"Chemicals & Drugs"	"We previously reported that some flavonoids have BCRP-inhibitory activity."
"FA"	17345086	9	"BCRP"	82	86	"Genes & Molecular Sequences"	"mitoxantrone"	159	171	"Chemicals & Drugs"	"Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone."
"PA"	17345086	0	"breast cancer resistance protein"	19	51	"Genes & Molecular Sequences"	"Flavonoids"	0	10	"Chemicals & Drugs"	"Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship."
"PA"	17345086	3	"BCRP"	75	79	"Genes & Molecular Sequences"	"flavonoids"	59	69	"Chemicals & Drugs"	"Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, P-gp-, and MRP1-mediated drug resistance."
"FA"	17345086	4	"BCRP"	104	108	"Genes & Molecular Sequences"	"flavonoids"	20	30	"Chemicals & Drugs"	"Reversal effects of flavonoids upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays."
"NA"	17345086	12	"MRP1"	48	52	"Genes & Molecular Sequences"	"flavonoids"	12	22	"Chemicals & Drugs"	"None of the flavonoids that we tested inhibited MRP1."
"PA"	17345086	9	"BCRP"	82	86	"Genes & Molecular Sequences"	"3',4',7-trimethoxyflavone"	30	55	"Chemicals & Drugs"	"Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone."
"FA"	17345086	11	"P-gp"	158	162	"Genes & Molecular Sequences"	"acacetin"	51	59	"Chemicals & Drugs"	"Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp."
"PA"	17345086	7	"BCRP"	16	20	"Genes & Molecular Sequences"	"topotecan"	88	97	"Chemicals & Drugs"	"The reversal of BCRP activity was tested by measuring the fluorescence of intracellular topotecan."
"FA"	17345086	11	"P-gp"	158	162	"Genes & Molecular Sequences"	"3',4',7-trimethoxyflavone"	21	46	"Chemicals & Drugs"	"Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp."
"PA"	17345086	13	"BCRP"	75	79	"Genes & Molecular Sequences"	"flavonoids"	44	54	"Chemicals & Drugs"	"Our present results thus indicate that many flavonoids selectively inhibit BCRP only."
"FA"	17345086	4	"P-gp"	43	47	"Genes & Molecular Sequences"	"flavonoids"	20	30	"Chemicals & Drugs"	"Reversal effects of flavonoids upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays."
"FA"	17345086	4	"MRP1"	53	57	"Genes & Molecular Sequences"	"flavonoids"	20	30	"Chemicals & Drugs"	"Reversal effects of flavonoids upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays."
"FA"	17345086	9	"BCRP"	82	86	"Genes & Molecular Sequences"	"SN-38"	135	140	"Chemicals & Drugs"	"Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone."
"PA"	18337476	2	"NPSR"	367	371	"Genes & Molecular Sequences"	"SHA 66"	78	84	"Chemicals & Drugs"	"We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR)."
"PA"	18337476	2	"NPS receptor"	353	365	"Genes & Molecular Sequences"	"SHA 68"	174	180	"Chemicals & Drugs"	"We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR)."
"PA"	18337476	7	"NPS"	95	98	"Genes & Molecular Sequences"	"SHA 68"	42	48	"Chemicals & Drugs"	"Furthermore, peripheral administration of SHA 68 in mice (50 mg/kg i.p.) is able to antagonize NPS-induced horizontal and vertical activity as well as stereotypic behavior."
"PA"	18337476	0	"neuropeptide S receptor"	194	217	"Genes & Molecular Sequences"	"SHA 68"	155	161	"Chemicals & Drugs"	"Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor."
"PA"	18337476	2	"NPS receptor"	353	365	"Genes & Molecular Sequences"	"SHA 66"	78	84	"Chemicals & Drugs"	"We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR)."
"PA"	18337476	2	"NPSR"	367	371	"Genes & Molecular Sequences"	"SHA 68"	174	180	"Chemicals & Drugs"	"We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR)."
"PA"	18337476	3	"NPSR"	92	96	"Genes & Molecular Sequences"	"SHA 68"	55	61	"Chemicals & Drugs"	"The compounds block NPS-induced Ca2+ mobilization, and SHA 68 shows displaceable binding to NPSR in the nanomolar range."
"PA"	18337476	8	"NPS"	119	122	"Genes & Molecular Sequences"	"SHA 68"	11	17	"Chemicals & Drugs"	"Therefore, SHA 68 could be a useful tool to characterize physiological functions and pharmacological parameters of the NPS system in vitro and in vivo."
"PA"	18927209	5	"mTOR"	100	104	"Genes & Molecular Sequences"	"P2281"	85	90	"Chemicals & Drugs"	"In vitro studies using Western blot analysis and cell-based ELISA assays showed that P2281 inhibits mTOR activity in colon cancer cells."
"PA"	18927209	7	"mTOR"	596	600	"Genes & Molecular Sequences"	"P2281"	557	562	"Chemicals & Drugs"	"In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR."
"FA"	18927209	6	"TNF-alpha"	135	144	"Genes & Molecular Sequences"	"P2281"	203	208	"Chemicals & Drugs"	"In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on T cell function."
"PA"	18927209	6	"IFN-gamma"	106	115	"Genes & Molecular Sequences"	"P2281"	203	208	"Chemicals & Drugs"	"In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on T cell function."
"PA"	18927209	7	"mTOR"	596	600	"Genes & Molecular Sequences"	"DSS"	570	573	"Chemicals & Drugs"	"In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR."
"PA"	18927209	7	"mTOR"	596	600	"Genes & Molecular Sequences"	"dextran sulfate sodium"	7	29	"Chemicals & Drugs"	"In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR."
"PA"	17167170	4	"caspase-3"	261	270	"Genes & Molecular Sequences"	"GW501516"	51	59	"Chemicals & Drugs"	"In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition."
"PA"	17167170	4	"caspase-3"	261	270	"Genes & Molecular Sequences"	"L-165041"	39	47	"Chemicals & Drugs"	"In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition."
"FA"	18341639	0	"FLT3 internal tandem duplication"	136	168	"Genes & Molecular Sequences"	"lestaurtinib"	105	117	"Chemicals & Drugs"	"Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication."
"PA"	18341639	5	"FLT3/WT"	61	68	"SNP & Sequence variations"	"lestaurtinib"	45	57	"Chemicals & Drugs"	"FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004)."
"FA"	18341639	2	"FLT3/TKD+"	134	143	"SNP & Sequence variations"	"FLT3 inhibitors"	72	87	"Chemicals & Drugs"	"Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level."
"FA"	18341639	0	"tyrosine kinase domain mutation of FLT3"	43	82	"Genes & Molecular Sequences"	"lestaurtinib"	105	117	"Chemicals & Drugs"	"Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication."
"NA"	18341639	4	"FLT3/TKD"	182	190	"SNP & Sequence variations"	"cytarabine"	139	149	"Chemicals & Drugs"	"All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact."
"FA"	18341639	0	"FLT3 internal tandem duplication"	136	168	"Genes & Molecular Sequences"	"lestaurtinib"	105	117	"Chemicals & Drugs"	"Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication."
"FA"	18341639	8	"FLT3/TKD+"	27	36	"SNP & Sequence variations"	"FLT3 inhibitors"	129	144	"Chemicals & Drugs"	"These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors."
"FA"	18341639	6	"FLT3/TKD+"	99	108	"SNP & Sequence variations"	"lestaurtinib"	50	62	"Chemicals & Drugs"	"There was no correlation between mutant level and lestaurtinib sensitivity for either FLT3/ITD+ or FLT3/TKD+ cells."
"PA"	18341639	5	"FLT3/TKD+"	0	9	"SNP & Sequence variations"	"lestaurtinib"	45	57	"Chemicals & Drugs"	"FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004)."
"FA"	18341639	8	"FLT3/WT"	41	48	"SNP & Sequence variations"	"FLT3 inhibitors"	129	144	"Chemicals & Drugs"	"These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors."
"PA"	18341639	4	"FLT3/ITD"	87	95	"SNP & Sequence variations"	"cytarabine"	139	149	"Chemicals & Drugs"	"All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact."
"PA"	18676772	9	"telomerase"	89	99	"Genes & Molecular Sequences"	"GRN163L"	65	72	"Chemicals & Drugs"	"The treatment of adenocarcinoma cells with telomerase inhibitor, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis."
"PA"	17805244	2	"PPARgamma"	230	239	"Genes & Molecular Sequences"	"NSAID"	192	197	"Chemicals & Drugs"	"The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD is mediated by PPARgamma."
"PA"	17805244	2	"PPARgamma"	230	239	"Genes & Molecular Sequences"	"NSAIDs"	14	20	"Chemicals & Drugs"	"The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD is mediated by PPARgamma."
"FA"	17893038	0	"RAGE"	25	29	"Genes & Molecular Sequences"	"statins"	80	87	"Chemicals & Drugs"	"Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins."
"PA"	18202009	4	"CXCR4"	67	72	"Genes & Molecular Sequences"	"imatinib"	24	32	"Chemicals & Drugs"	"In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased CXCR4 expression and migration."
"SA"	18202009	3	"CXCR4"	79	84	"Genes & Molecular Sequences"	"INNO-406"	57	65	"Chemicals & Drugs"	"We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells."
"PA"	18202009	5	"CXCR4"	17	22	"Genes & Molecular Sequences"	"imatinib"	115	123	"Chemicals & Drugs"	"This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha."
"PA"	18202009	0	"CXCR4"	0	5	"Genes & Molecular Sequences"	"imatinib"	23	31	"Chemicals & Drugs"	"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells."
"FA"	18202009	5	"CXCR4"	17	22	"Genes & Molecular Sequences"	"IFN-alpha"	127	136	"Chemicals & Drugs"	"This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha."
"PA"	18202009	4	"CXCR4"	67	72	"Genes & Molecular Sequences"	"INNO-406"	34	42	"Chemicals & Drugs"	"In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased CXCR4 expression and migration."
"PA"	18202009	9	"CXCR4"	61	66	"Genes & Molecular Sequences"	"imatinib"	70	78	"Chemicals & Drugs"	"Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells."
"PA"	18202009	4	"CXCR4"	67	72	"Genes & Molecular Sequences"	"IFN-alpha"	47	56	"Chemicals & Drugs"	"In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased CXCR4 expression and migration."
"SA"	18202009	3	"CXCR4"	79	84	"Genes & Molecular Sequences"	"imatinib"	45	53	"Chemicals & Drugs"	"We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells."
"PA"	18348297	13	"adiponectin"	106	117	"Genes & Molecular Sequences"	"GnRH agonists"	39	52	"Chemicals & Drugs"	"In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level."
"PA"	18348297	13	"HDL cholesterol"	85	100	"Genes & Molecular Sequences"	"GnRH agonists"	39	52	"Chemicals & Drugs"	"In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level."
"NA"	18348297	13	"C-reactive protein"	179	197	"Genes & Molecular Sequences"	"GnRH agonists"	39	52	"Chemicals & Drugs"	"In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level."
"PA"	18497344	5	"insulin-like growth factor binding protein 5"	63	107	"Genes & Molecular Sequences"	"progesterone"	41	53	"Chemicals & Drugs"	"Also upregulated were genes inhibited by progesterone, such as insulin-like growth factor binding protein 5."
"PA"	18524848	6	"GLI"	32	35	"Genes & Molecular Sequences"	"doxorubicin"	270	281	"Chemicals & Drugs"	"Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin."
"PA"	18155663	6	"SOD"	92	95	"Genes & Molecular Sequences"	"RZG"	0	3	"Chemicals & Drugs"	"RZG treatment led to a limitation of oxidative stress exemplified by an increase of GPx and SOD expression."
"NA"	18155663	2	"PDX-1"	93	98	"Genes & Molecular Sequences"	"RZG"	21	24	"Chemicals & Drugs"	"We demonstrated that RZG beneficial effects on insulin secretion and apoptosis did not imply PDX-1 or insulin gene modulation."
"NA"	18155663	2	"insulin"	102	109	"Genes & Molecular Sequences"	"RZG"	21	24	"Chemicals & Drugs"	"We demonstrated that RZG beneficial effects on insulin secretion and apoptosis did not imply PDX-1 or insulin gene modulation."
"PA"	18155663	6	"GPx"	84	87	"Genes & Molecular Sequences"	"RZG"	0	3	"Chemicals & Drugs"	"RZG treatment led to a limitation of oxidative stress exemplified by an increase of GPx and SOD expression."
"PA"	17535976	7	"PPARgamma"	184	193	"Genes & Molecular Sequences"	"bisphenol A diglycidyl ether"	58	86	"Chemicals & Drugs"	"The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a PPARgamma antagonist, and by knockdown of PPARgamma expression, indicating the involvement of PPARgamma in these actions."
"PA"	19047160	6	"p53/56 Lyn"	27	37	"Genes & Molecular Sequences"	"nilotinib"	194	203	"Chemicals & Drugs"	"Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib."
"PA"	19047160	5	"P-glycoprotein"	82	96	"Genes & Molecular Sequences"	"nilotinib"	15	24	"Chemicals & Drugs"	"We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding."
"SA"	19047160	0	"Pgp"	61	64	"Genes & Molecular Sequences"	"nilotinib"	28	37	"Chemicals & Drugs"	"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression."
"SA"	19047160	0	"Src kinase"	69	79	"Genes & Molecular Sequences"	"nilotinib"	28	37	"Chemicals & Drugs"	"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression."
"PA"	19047160	9	"p53/56 Lyn"	182	192	"Genes & Molecular Sequences"	"dasatinib"	13	22	"Chemicals & Drugs"	"In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn."
"FA"	19047160	8	"Bcr-Abl"	103	110	"Genes & Molecular Sequences"	"PP1"	27	30	"Chemicals & Drugs"	"Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity."
"FA"	19047160	8	"Bcr-Abl"	103	110	"Genes & Molecular Sequences"	"PP2"	35	38	"Chemicals & Drugs"	"Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity."
"PA"	19047160	5	"P-glycoprotein"	82	96	"Genes & Molecular Sequences"	"PSC833"	117	123	"Chemicals & Drugs"	"We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding."
"PA"	19047160	6	"Lyn"	131	134	"Genes & Molecular Sequences"	"nilotinib"	194	203	"Chemicals & Drugs"	"Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib."
"PA"	19047160	9	"Lyn"	115	118	"Genes & Molecular Sequences"	"dasatinib"	13	22	"Chemicals & Drugs"	"In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn."
"PA"	19047160	5	"P-glycoprotein"	82	96	"Genes & Molecular Sequences"	"verapamil"	104	113	"Chemicals & Drugs"	"We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding."
"PA"	19047160	10	"Lyn"	126	129	"Genes & Molecular Sequences"	"imatinib"	61	69	"Chemicals & Drugs"	"Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance."
"PA"	19047160	7	"Lyn mRNA"	75	83	"Genes & Molecular Sequences"	"nilotinib"	21	30	"Chemicals & Drugs"	"Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML."
"PA"	19047160	9	"Bcr-Abl"	149	156	"Genes & Molecular Sequences"	"dasatinib"	13	22	"Chemicals & Drugs"	"In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn."
"FA"	19047160	8	"Bcr-Abl"	103	110	"Genes & Molecular Sequences"	"Src kinase inhibitors"	4	25	"Chemicals & Drugs"	"Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity."
"PA"	19047160	10	"Lyn"	126	129	"Genes & Molecular Sequences"	"nilotinib"	133	142	"Chemicals & Drugs"	"Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance."
"SA"	19047160	0	"BCR-ABL"	52	59	"Genes & Molecular Sequences"	"nilotinib"	28	37	"Chemicals & Drugs"	"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression."
"FA"	18234154	0	"ABCC1"	85	90	"Genes & Molecular Sequences"	"CBT-1((R))"	149	159	"Chemicals & Drugs"	"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))."
"FA"	18234154	0	"ABCB1"	30	35	"Genes & Molecular Sequences"	"CBT-1((R))"	149	159	"Chemicals & Drugs"	"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))."
"FA"	18234154	0	"P-glycoprotein"	14	28	"Genes & Molecular Sequences"	"CBT-1((R))"	149	159	"Chemicals & Drugs"	"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))."
"PA"	18234154	7	"Pgp"	143	146	"Genes & Molecular Sequences"	"CBT-1"	114	119	"Chemicals & Drugs"	"CBT-1 was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated Pgp-mediated ATP hydrolysis."
"NA"	18234154	9	"ABCG2"	56	61	"Genes & Molecular Sequences"	"CBT-1"	0	5	"Chemicals & Drugs"	"CBT-1 at 25 microM did not have a significant effect on ABCG2-mediated pheophorbide a transport."
"PA"	18234154	6	"Pgp"	43	46	"Genes & Molecular Sequences"	"paclitaxel"	83	93	"Chemicals & Drugs"	"Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells."
"PA"	18234154	8	"MRP1"	78	82	"Genes & Molecular Sequences"	"CBT-1"	40	45	"Chemicals & Drugs"	"In MRP1-overexpressing cells, 10 microM CBT-1 was found to completely inhibit MRP1-mediated calcein transport."
"PA"	18234154	11	"Pgp"	131	134	"Genes & Molecular Sequences"	"CBT-1"	0	5	"Chemicals & Drugs"	"CBT-1 is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed."
"FA"	18234154	11	"ABC transporters"	29	45	"Genes & Molecular Sequences"	"CBT-1"	0	5	"Chemicals & Drugs"	"CBT-1 is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed."
"FA"	18234154	0	"multidrug resistance-associated protein"	42	81	"Genes & Molecular Sequences"	"CBT-1((R))"	149	159	"Chemicals & Drugs"	"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))."
"FA"	18234154	3	"Pgp"	78	81	"Genes & Molecular Sequences"	"CBT-1"	0	5	"Chemicals & Drugs"	"CBT-1 is a bisbenzylisoquinoline plant alkyloid currently in development as a Pgp inhibitor."
"PA"	18234154	6	"Pgp"	43	46	"Genes & Molecular Sequences"	"vinblastine"	70	81	"Chemicals & Drugs"	"Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells."
"PA"	18234154	11	"MRP1"	142	146	"Genes & Molecular Sequences"	"CBT-1"	0	5	"Chemicals & Drugs"	"CBT-1 is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed."
"PA"	17304149	1	"P-glycoprotein"	68	82	"Genes & Molecular Sequences"	"paroxetine"	39	49	"Chemicals & Drugs"	"A recent in vitro study has shown that paroxetine is a substrate of P-glycoprotein."
"SA"	17304149	9	"P-glycoprotein"	138	152	"Genes & Molecular Sequences"	"paroxetine"	180	190	"Chemicals & Drugs"	"The present study demonstrated that the bioavailability of paroxetine was increased by itraconazole, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of paroxetine."
"FA"	17304149	2	"P-glycoprotein"	72	86	"Genes & Molecular Sequences"	"paroxetine"	114	124	"Chemicals & Drugs"	"However, there was no in vivo information indicating the involvement of P-glycoprotein on the pharmacokinetics of paroxetine."
"PA"	18165569	10	"CYP2D6"	55	61	"Genes & Molecular Sequences"	"epidural infusion of ropivacaine"	13	45	"Chemicals & Drugs"	"A continuous epidural infusion of ropivacaine inhibits CYP2D6 activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation."
"PA"	18165569	1	"CYP2D6"	66	72	"Genes & Molecular Sequences"	"Ropivacaine"	0	11	"Chemicals & Drugs"	"Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit CYP2D6 in."
"PA"	18165569	6	"CYP2D6"	51	57	"Genes & Molecular Sequences"	"debrisoquine"	24	36	"Chemicals & Drugs"	"Patients received 10 mg debrisoquine (a marker for CYP2D6 activity) before surgery and after 40 h epidural infusion."
"PA"	18165569	1	"CYP2D6"	66	72	"Genes & Molecular Sequences"	"pipecoloxylidide"	40	56	"Chemicals & Drugs"	"Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit CYP2D6 in."
"PA"	18165569	10	"CYP2D6"	55	61	"Genes & Molecular Sequences"	"debrisoquine"	160	172	"Chemicals & Drugs"	"A continuous epidural infusion of ropivacaine inhibits CYP2D6 activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation."
"SA"	17241106	16	"LRP5"	19	23	"Genes & Molecular Sequences"	"osteoporosis"	80	92	"Diseases & Disorders"	"Our work supported LRP5 genetic variants as possible susceptibility factors for osteoporosis and fractures in humans."
"SA"	17241106	17	"rs491347"	20	28	"SNP & Sequence variations"	"osteoporosis"	108	120	"Diseases & Disorders"	"Especially, the SNP rs491347 and its strongly associated SNPs (e.g., rs1784235) could be important to human osteoporosis phenotypes."
"SA"	17241106	17	"rs1784235"	69	78	"SNP & Sequence variations"	"osteoporosis"	108	120	"Diseases & Disorders"	"Especially, the SNP rs491347 and its strongly associated SNPs (e.g., rs1784235) could be important to human osteoporosis phenotypes."
"FA"	18697826	0	"fetal haemoglobin"	93	110	"Genes & Molecular Sequences"	"beta-thalassaemia"	132	149	"Diseases & Disorders"	"The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia."
"PA"	18697826	1	"HbF"	19	22	"Genes & Molecular Sequences"	"HBB disorders"	64	77	"Diseases & Disorders"	"Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders."
"PA"	18697826	1	"Fetal haemoglobin"	0	17	"Genes & Molecular Sequences"	"HBB disorders"	64	77	"Diseases & Disorders"	"Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders."
"FA"	18697826	0	"HBS1L-MYB"	4	13	"Genes & Molecular Sequences"	"beta-thalassaemia"	132	149	"Diseases & Disorders"	"The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia."
"FA"	18697826	0	"6q23"	46	50	"Genes & Molecular Sequences"	"beta-thalassaemia"	132	149	"Diseases & Disorders"	"The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia."
"FA"	18697826	7	"HbF"	87	90	"Genes & Molecular Sequences"	"HBB disorders"	196	209	"Diseases & Disorders"	"Functional studies to unravel the biological significance of this region in regulating HbF production is clearly indicated, which may lead to new strategies to modify the disease course of severe HBB disorders."
"PA"	18322311	0	"TNFalpha gene polymorphisms"	16	43	"Genes & Molecular Sequences"	"multiple sclerosis"	69	87	"Diseases & Disorders"	"IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis."
"FA"	18322311	7	"IL-1alpha TT -889"	35	52	"SNP & Sequence variations"	"multiple sclerosis"	406	424	"Diseases & Disorders"	"On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients."
"PA"	18322311	7	"TNFalpha G -308 allele"	138	160	"Genes & Molecular Sequences"	"multiple sclerosis"	406	424	"Diseases & Disorders"	"On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients."
"PA"	18322311	0	"IL-1"	0	4	"Genes & Molecular Sequences"	"multiple sclerosis"	69	87	"Diseases & Disorders"	"IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis."
"PA"	18347176	0	"T393C polymorphism of the GNAS1"	127	158	"SNP & Sequence variations"	"oropharyngeal"	37	50	"Diseases & Disorders"	"Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene."
"PA"	18347176	0	"T393C polymorphism of the GNAS1"	127	158	"SNP & Sequence variations"	"hypopharyngeal squamous cell carcinoma"	55	93	"Diseases & Disorders"	"Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene."
"FA"	18347176	9	"T393C"	4	9	"SNP & Sequence variations"	"hypopharyngeal cancer"	130	151	"Diseases & Disorders"	"The T393C SNP could be considered as a genetic marker to predict the clinical course of patients suffering from oropharyngeal and hypopharyngeal cancer."
"PA"	18347176	9	"T393C"	4	9	"SNP & Sequence variations"	"oropharyngeal"	112	125	"Diseases & Disorders"	"The T393C SNP could be considered as a genetic marker to predict the clinical course of patients suffering from oropharyngeal and hypopharyngeal cancer."
"FA"	18347176	3	"T393C"	28	33	"SNP & Sequence variations"	"oropharyngeal"	121	134	"Diseases & Disorders"	"The prognostic value of the T393C SNP was evaluated in an unselected series of patients treated with curative intent for oropharyngeal and hypopharyngeal squamous cell carcinomas, including all tumor stages with different therapeutic regimens."
"FA"	17430902	3	"Wnt"	69	72	"Genes & Molecular Sequences"	"colon cancer"	25	37	"Diseases & Disorders"	"However, the majority of colon cancer cells have deregulation of the Wnt/beta-catenin pathway."
"FA"	17430902	0	"Kr\FCppel-like factor 5"	87	108	"Genes & Molecular Sequences"	"colon cancer"	51	63	"Diseases & Disorders"	"Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kr\FCppel-like factor 5."
"PA"	17430902	2	"beta-catenin"	99	111	"Genes & Molecular Sequences"	"colon cancer"	57	69	"Diseases & Disorders"	"A recent study showed that LPA-mediated proliferation of colon cancer cells requires activation of beta-catenin."
"PA"	18930278	6	"CYP3A5 A6986G genotype *3/*3"	29	57	"Genes & Molecular Sequences"	"leukocytopenia"	211	225	"Diseases & Disorders"	"On multivariate analysis the CYP3A5 A6986G genotype *3/*3 (OR 8.205, 95% CI 1.616-41.667, p = 0.011) and smaller number of treatment cycles (OR 0.156, 95% CI 0.037-0.659, p = 0.011) were independent factors for leukocytopenia (grade 3 or greater) throughout the period of chemotherapy."
"PA"	18930278	8	"A6986G polymorphism of CYP3A5"	4	33	"Genes & Molecular Sequences"	"leukocytopenia"	151	165	"Diseases & Disorders"	"The A6986G polymorphism of CYP3A5, which is involved in the metabolism of vinblastine and doxorubicin, might be a genetic predictor of the severity of leukocytopenia induced by chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin."
"SA"	17593927	11	"XRCC1"	0	5	"Genes & Molecular Sequences"	"gastric cancer"	61	75	"Diseases & Disorders"	"XRCC1 genotyping might make tailor chemotherapy possible for gastric cancer patients treated with oxaliplatin-based chemotherapy."
"PA"	17593927	0	"Polymorphism of XRCC1"	0	21	"Genes & Molecular Sequences"	"gastric cancer"	51	65	"Diseases & Disorders"	"Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population."
"PA"	19097922	1	"CYP4F2"	45	51	"Genes & Molecular Sequences"	"myocardial infarction"	61	82	"Diseases & Disorders"	"This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200)."
"PA"	19097922	0	"CYP4F2"	19	25	"Genes & Molecular Sequences"	"myocardial infarction"	47	68	"Diseases & Disorders"	"A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men."
"PA"	19097922	2	"rs2108622"	31	40	"SNP & Sequence variations"	"MI"	170	172	"Diseases & Disorders"	"For men, G allele frequency of rs2108622 and frequency of the T-C-G haplotype were significantly higher, and frequency of the T-C-A haplotype was significantly lower for MI patients than for controls (P=0.006, P=0.001 and P=0.002, respectively)."
"FA"	19097922	1	"CYP4F2"	45	51	"Genes & Molecular Sequences"	"MI"	139	141	"Diseases & Disorders"	"This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200)."
"PA"	17631643	6	"ALDH2 Ex1+82A>G"	19	34	"Genes & Molecular Sequences"	"stomach cancer"	78	92	"Diseases & Disorders"	"When stratified by ALDH2 Ex1+82A>G polymorphism, alcohol-related increases in stomach cancer risk were restricted to individuals with the AG/GG genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years."
"PA"	19035720	1	"COL1A2"	4	10	"Genes & Molecular Sequences"	"IAs"	96	99	"Diseases & Disorders"	"The COL1A2 gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population."
"PA"	19035720	1	"COL1A2"	4	10	"Genes & Molecular Sequences"	"intracranial aneurysms"	72	94	"Diseases & Disorders"	"The COL1A2 gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population."
"SA"	19035720	6	"rs42524"	4	11	"SNP & Sequence variations"	"IAs"	79	82	"Diseases & Disorders"	"The rs42524 polymorphism of COL1A2 could be a genetic risk factor for sporadic IAs among individuals of Chinese Han ethnicity."
"FA"	19035720	2	"COL1A2"	115	121	"Genes & Molecular Sequences"	"IAs"	153	156	"Diseases & Disorders"	"In the present study, the authors investigated the correlation between the presence of the rs42524 polymorphism in COL1A2 and the occurrence of sporadic IAs in Chinese patients."
"PA"	19035720	7	"COL1A2"	59	65	"Genes & Molecular Sequences"	"IAs"	70	73	"Diseases & Disorders"	"This study is the first to confirm the association between COL1A2 and IAs."
"FA"	19035720	6	"COL1A2"	28	34	"Genes & Molecular Sequences"	"IAs"	79	82	"Diseases & Disorders"	"The rs42524 polymorphism of COL1A2 could be a genetic risk factor for sporadic IAs among individuals of Chinese Han ethnicity."
"FA"	17548585	6	"TLR"	133	136	"Genes & Molecular Sequences"	"leprosy"	74	81	"Diseases & Disorders"	"Surprisingly, the 602S allele is associated with a decreased incidence of leprosy, suggesting that Mycobacterium leprae subverts the TLR system as a mechanism of immune evasion."
"PA"	17548585	0	"TLR1"	97	101	"Genes & Molecular Sequences"	"leprosy"	123	130	"Diseases & Disorders"	"Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy."
"PA"	17548585	6	"602S"	18	22	"SNP & Sequence variations"	"leprosy"	74	81	"Diseases & Disorders"	"Surprisingly, the 602S allele is associated with a decreased incidence of leprosy, suggesting that Mycobacterium leprae subverts the TLR system as a mechanism of immune evasion."
"PA"	17186014	10	"TRAIL"	64	69	"Genes & Molecular Sequences"	"prostate cancer"	138	153	"Diseases & Disorders"	"These results suggest that combination of HDACi with adenoviral TRAIL gene therapy may be a new therapeutic approach for the treatment of prostate cancer that warrants further investigation."
"PA"	17433748	0	"ALDH7A1"	85	92	"Genes & Molecular Sequences"	"pyridoxine dependent seizures"	43	72	"Diseases & Disorders"	"Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis."
"FA"	17433748	2	"ALDH7A1"	48	55	"Genes & Molecular Sequences"	"PDS"	88	91	"Diseases & Disorders"	"Recently, mutations have been identified in the ALDH7A1 gene in Caucasian families with PDS."
"PA"	19110417	1	"Cytochrome P450 1A1"	0	19	"Genes & Molecular Sequences"	"hepatocellular carcinoma"	90	114	"Diseases & Disorders"	"Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (HCC)."
"SA"	19110417	2	"CYP1A1"	56	62	"Genes & Molecular Sequences"	"HCC"	70	73	"Diseases & Disorders"	"However, the contribution of common genetic variants in CYP1A1 to the HCC risk in Chinese populations has not been thoroughly investigated."
"PA"	19110417	1	"Cytochrome P450 1A1"	0	19	"Genes & Molecular Sequences"	"HCC"	116	119	"Diseases & Disorders"	"Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (HCC)."
"PA"	19110417	10	"TTAC/CCAG"	29	38	"SNP & Sequence variations"	"HCC"	75	78	"Diseases & Disorders"	"Interestingly, the diplotype TTAC/CCAG also conferred an increased risk of HCC (OR 1.76, 95% CI 1.22-2.54, P=0.003)."
"PA"	19110417	6	"rs2198843"	110	119	"SNP & Sequence variations"	"HCC"	188	191	"Diseases & Disorders"	"To summarise, we detected an increased HCC risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of HCC (OR 0.70. 95% CI 0.52-0.94) associated with homozygote carriers of rs4886605 variant."
"PA"	19110417	6	"rs4886605"	259	268	"SNP & Sequence variations"	"HCC"	188	191	"Diseases & Disorders"	"To summarise, we detected an increased HCC risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of HCC (OR 0.70. 95% CI 0.52-0.94) associated with homozygote carriers of rs4886605 variant."
"FA"	19110417	8	"CYP1A1"	28	34	"Genes & Molecular Sequences"	"HCC"	101	104	"Diseases & Disorders"	"Compared to the most common CYP1A1 haplotype CCAG, the haplotype TTGC conferred an increased risk of HCC (OR 1.26, 95% CI 1.04-1.52)."
"FA"	19110417	3	"CYP1A1"	147	153	"Genes & Molecular Sequences"	"HCC"	209	212	"Diseases & Disorders"	"In this study, we examined the association between HCC and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 cancer-free controls, from a Han Chinese population."
"SA"	19110417	11	"CYP1A1"	54	60	"Genes & Molecular Sequences"	"HCC"	97	100	"Diseases & Disorders"	"Our results suggested that common genetic variants in CYP1A1 may modulate the risk of developing HCC in the study population, particularly in non-smokers."
"PA"	17582399	1	"Amyloid beta protein"	0	20	"Genes & Molecular Sequences"	"Alzheimer's disease"	65	84	"Diseases & Disorders"	"Amyloid beta protein (Abeta) levels are elevated in the brain of Alzheimer's disease patients."
"PA"	17582399	1	"Abeta"	22	27	"Genes & Molecular Sequences"	"Alzheimer's disease"	65	84	"Diseases & Disorders"	"Amyloid beta protein (Abeta) levels are elevated in the brain of Alzheimer's disease patients."
"FA"	17582399	0	"amyloid beta protein"	5	25	"Genes & Molecular Sequences"	"Alzheimer's disease"	102	121	"Diseases & Disorders"	"Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment."
"PA"	18381438	1	"p53"	260	263	"Genes & Molecular Sequences"	"solid tumors"	175	187	"Diseases & Disorders"	"The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy."
"FA"	17589947	1	"TNF)-alpha"	223	233	"Genes & Molecular Sequences"	"IBD"	290	293	"Diseases & Disorders"	"To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity."
"FA"	17589947	1	"TNF)-alpha"	223	233	"Genes & Molecular Sequences"	"inflammatory bowel diseases"	261	288	"Diseases & Disorders"	"To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity."
"PA"	17589947	4	"TIMP-1 genotype TT"	4	22	"Genes & Molecular Sequences"	"CD"	83	85	"Diseases & Disorders"	"The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025)."
"PA"	17589947	4	"TIMP-1 genotype TT"	4	22	"Genes & Molecular Sequences"	"fistulae"	237	245	"Diseases & Disorders"	"The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025)."
"PA"	17589947	6	"5T5T genotype at MMP-3 SNP -1613 5T/6T"	4	42	"SNP & Sequence variations"	"CD"	93	95	"Diseases & Disorders"	"The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017)."
"PA"	17589947	7	"TIMP-1"	61	67	"Genes & Molecular Sequences"	"CD"	85	87	"Diseases & Disorders"	"Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation."
"PA"	17589947	7	"MMP-3"	72	77	"Genes & Molecular Sequences"	"CD"	85	87	"Diseases & Disorders"	"Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation."
"FA"	17589947	1	"tissue inhibitors of metalloproteinases"	143	182	"Genes & Molecular Sequences"	"IBD"	290	293	"Diseases & Disorders"	"To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity."
"FA"	17589947	1	"tissue inhibitors of metalloproteinases"	143	182	"Genes & Molecular Sequences"	"inflammatory bowel diseases"	261	288	"Diseases & Disorders"	"To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity."
"PA"	17589947	1	"tumor necrosis factor"	200	221	"Genes & Molecular Sequences"	"inflammatory bowel diseases"	261	288	"Diseases & Disorders"	"To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity."
"FA"	17589947	1	"tumor necrosis factor"	200	221	"Genes & Molecular Sequences"	"IBD"	290	293	"Diseases & Disorders"	"To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity."
"FA"	17589947	4	"SNP +372 T/C"	48	60	"SNP & Sequence variations"	"fistulae"	237	245	"Diseases & Disorders"	"The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025)."
"PA"	17589947	4	"SNP +372 T/C"	48	60	"SNP & Sequence variations"	"CD"	83	85	"Diseases & Disorders"	"The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025)."
"FA"	17589947	6	"MMP-3"	21	26	"Genes & Molecular Sequences"	"CD"	93	95	"Diseases & Disorders"	"The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017)."
"PA"	17096334	0	"NPAS2"	41	46	"Genes & Molecular Sequences"	"non-Hodgkin's lymphoma"	85	107	"Diseases & Disorders"	"Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma."
"FA"	17096334	0	"Ala394Thr"	0	9	"SNP & Sequence variations"	"non-Hodgkin's lymphoma"	85	107	"Diseases & Disorders"	"Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma."
"PA"	18071766	4	"stx2"	22	26	"Genes & Molecular Sequences"	"HUS"	118	121	"Diseases & Disorders"	"STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying stx2vha."
"PA"	18071766	4	"stx2"	22	26	"Genes & Molecular Sequences"	"hemolytic-uremic syndrome"	91	116	"Diseases & Disorders"	"STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying stx2vha."
"PA"	18071766	4	"stx2"	22	26	"Genes & Molecular Sequences"	"bloody diarrhea"	126	141	"Diseases & Disorders"	"STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying stx2vha."
"PA"	18071766	6	"stx2"	157	161	"Genes & Molecular Sequences"	"STEC O157 infection"	85	104	"Diseases & Disorders"	"We conclude that stx genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the stx2 genotype strains than in the stx2vha genotype strains, as reported previously by other researchers."
"PA"	17258816	5	"ME2"	81	84	"Genes & Molecular Sequences"	"psychosis"	158	167	"Diseases & Disorders"	"Subsequent analysis of individual SNPs in strong linkage disequilibrium with the ME2 gene revealed one SNP and one haplotype associated with the phenotype of psychosis in the CVCR sample."
"PA"	17258816	6	"ME2"	0	3	"Genes & Molecular Sequences"	"bipolar disorder"	111	127	"Diseases & Disorders"	"ME2 interacts directly with the malate shuttle system, which has been shown to be altered in schizophrenia and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid."
"PA"	17258816	6	"ME2"	0	3	"Genes & Molecular Sequences"	"schizophrenia"	93	106	"Diseases & Disorders"	"ME2 interacts directly with the malate shuttle system, which has been shown to be altered in schizophrenia and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid."
"PA"	17258816	7	"ME2"	65	68	"Genes & Molecular Sequences"	"psychotic"	98	107	"Diseases & Disorders"	"The present study suggests that genetic variation in or near the ME2 gene is associated with both psychotic and manic disorders, including schizophrenia and bipolar disorder."
"PA"	17258816	7	"ME2"	65	68	"Genes & Molecular Sequences"	"manic disorders"	112	127	"Diseases & Disorders"	"The present study suggests that genetic variation in or near the ME2 gene is associated with both psychotic and manic disorders, including schizophrenia and bipolar disorder."
"PA"	17258816	7	"ME2"	65	68	"Genes & Molecular Sequences"	"schizophrenia"	139	152	"Diseases & Disorders"	"The present study suggests that genetic variation in or near the ME2 gene is associated with both psychotic and manic disorders, including schizophrenia and bipolar disorder."
"PA"	17258816	7	"ME2"	65	68	"Genes & Molecular Sequences"	"bipolar disorder"	157	173	"Diseases & Disorders"	"The present study suggests that genetic variation in or near the ME2 gene is associated with both psychotic and manic disorders, including schizophrenia and bipolar disorder."
"PA"	17270229	2	"p53"	31	34	"Genes & Molecular Sequences"	"cancers"	159	166	"Diseases & Disorders"	"Genetic alterations within the p53 gene have been shown to have a direct correlation with cancer development and have been shown to occur in nearly 50% of all cancers."
"PA"	17270229	5	"p53"	34	37	"Genes & Molecular Sequences"	"non-melanoma skin cancers"	108	133	"Diseases & Disorders"	"This review discusses the role of p53 from normal function and its dysfunction in pre-cancerous lesions and non-melanoma skin cancers."
"PA"	19100387	1	"CRP"	137	140	"Genes & Molecular Sequences"	"CKD"	175	178	"Diseases & Disorders"	"We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (CRP) gene promoter region for their effects on CRP levels in chronic kidney disease (CKD) patients before and after a successful kidney transplantation."
"PA"	19100387	1	"CRP"	137	140	"Genes & Molecular Sequences"	"chronic kidney disease"	151	173	"Diseases & Disorders"	"We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (CRP) gene promoter region for their effects on CRP levels in chronic kidney disease (CKD) patients before and after a successful kidney transplantation."
"SA"	18708184	1	"NRG3"	51	55	"Genes & Molecular Sequences"	"schizophrenia"	65	78	"Diseases & Disorders"	"The study investigated the possible association of NRG3 gene and schizophrenia in a Han Chinese population."
"PA"	18708184	8	"rs1937970-rs677221"	83	101	"SNP & Sequence variations"	"schizophrenia"	252	265	"Diseases & Disorders"	"In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected schizophrenia offspring were observed."
"PA"	18708184	5	"rs677221-C"	150	160	"SNP & Sequence variations"	"schizophrenia"	187	200	"Diseases & Disorders"	"In case-control samples, two SNPs (rs1937970 and rs677221) showed significant genotypic and allelic association with schizophrenia (all p < .05) with rs677221-C being the risk allele for schizophrenia (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858)."
"PA"	18708184	5	"rs1937970"	35	44	"SNP & Sequence variations"	"schizophrenia"	187	200	"Diseases & Disorders"	"In case-control samples, two SNPs (rs1937970 and rs677221) showed significant genotypic and allelic association with schizophrenia (all p < .05) with rs677221-C being the risk allele for schizophrenia (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858)."
"PA"	18708184	9	"NRG3"	29	33	"Genes & Molecular Sequences"	"schizophrenia"	68	81	"Diseases & Disorders"	"The result supports that the NRG3 gene is a susceptibility gene for schizophrenia."
"PA"	18708184	6	"Haplotypes GC"	0	13	"SNP & Sequence variations"	"schizophrenia"	81	94	"Diseases & Disorders"	"Haplotypes GC constructed by the two SNPs was also significantly associated with schizophrenia (permutation p value = .0047)."
"PA"	18708184	8	"haplotype AG"	138	150	"SNP & Sequence variations"	"schizophrenia"	252	265	"Diseases & Disorders"	"In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected schizophrenia offspring were observed."
"PA"	18708184	7	"rs1937970-A"	33	44	"SNP & Sequence variations"	"schizophrenic"	114	127	"Diseases & Disorders"	"In the independent trio samples, rs1937970-A and rs677221-G consistently showed significant under-transmission to schizophrenic offspring (unadjusted p = .003 and p = .004, respectively)."
"PA"	18708184	7	"rs677221-G"	49	59	"SNP & Sequence variations"	"schizophrenic"	114	127	"Diseases & Disorders"	"In the independent trio samples, rs1937970-A and rs677221-G consistently showed significant under-transmission to schizophrenic offspring (unadjusted p = .003 and p = .004, respectively)."
"PA"	18708184	8	"haplotype GC"	200	212	"SNP & Sequence variations"	"schizophrenia"	252	265	"Diseases & Disorders"	"In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected schizophrenia offspring were observed."
"PA"	18708184	0	"Neuregulin 3"	0	12	"Genes & Molecular Sequences"	"schizophrenia"	54	67	"Diseases & Disorders"	"Neuregulin 3 genetic variations and susceptibility to schizophrenia in a Chinese population."
"PA"	18708184	5	"rs677221"	49	57	"SNP & Sequence variations"	"schizophrenia"	187	200	"Diseases & Disorders"	"In case-control samples, two SNPs (rs1937970 and rs677221) showed significant genotypic and allelic association with schizophrenia (all p < .05) with rs677221-C being the risk allele for schizophrenia (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858)."
"SA"	19098911	6	"NLRP3"	31	36	"Genes & Molecular Sequences"	"Crohn's disease"	130	145	"Diseases & Disorders"	"These results suggest that the NLRP3 region is also implicated in the susceptibility of more common inflammatory diseases such as Crohn's disease."
"PA"	19098911	1	"NLRP3"	135	140	"Genes & Molecular Sequences"	"Crohn's disease"	204	219	"Diseases & Disorders"	"We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with Crohn's disease."
"PA"	19098911	1	"NALP3"	172	177	"Genes & Molecular Sequences"	"Crohn's disease"	204	219	"Diseases & Disorders"	"We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with Crohn's disease."
"PA"	19098911	0	"NLRP3"	23	28	"Genes & Molecular Sequences"	"Crohn's disease"	50	65	"Diseases & Disorders"	"Common variants in the NLRP3 region contribute to Crohn's disease susceptibility."
"SA"	19115152	4	"MDR1"	32	36	"Genes & Molecular Sequences"	"inflammatory bowel disease"	93	119	"Diseases & Disorders"	"Therefore, the mutations of the MDR1 gene are thought to be related with the pathogenesis of inflammatory bowel disease."
"FA"	19115152	10	"MDR1"	57	61	"Genes & Molecular Sequences"	"Crohn's disease"	105	120	"Diseases & Disorders"	"In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or ulcerative colitis."
"FA"	19115152	10	"MDR1"	57	61	"Genes & Molecular Sequences"	"ulcerative colitis"	124	142	"Diseases & Disorders"	"In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or ulcerative colitis."
"NA"	19115152	10	"G2677T/A"	19	27	"SNP & Sequence variations"	"Crohn's disease"	105	120	"Diseases & Disorders"	"In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or ulcerative colitis."
"NA"	19115152	10	"G2677T/A"	19	27	"SNP & Sequence variations"	"ulcerative colitis"	124	142	"Diseases & Disorders"	"In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or ulcerative colitis."
"FA"	19039095	1	"hairy and enhancer of split homologue-1"	14	53	"Genes & Molecular Sequences"	"breast cancer"	134	147	"Diseases & Disorders"	"Regulation of hairy and enhancer of split homologue-1 (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human breast cancer cells."
"FA"	19039095	0	"hairy and enhancer of split homolog-1"	37	74	"Genes & Molecular Sequences"	"breast cancer"	94	107	"Diseases & Disorders"	"Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in breast cancer cells is mediated via a 3' distal element."
"PA"	19039095	1	"HES-1"	55	60	"Genes & Molecular Sequences"	"breast cancer"	134	147	"Diseases & Disorders"	"Regulation of hairy and enhancer of split homologue-1 (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human breast cancer cells."
"FA"	19107206	4	"rs13199524"	91	101	"SNP & Sequence variations"	"HIV"	189	192	"Diseases & Disorders"	"Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers."
"PA"	19107206	1	"Chemokine receptor"	62	80	"Genes & Molecular Sequences"	"HIV-1 disease"	24	37	"Diseases & Disorders"	"Previous studies of the HIV-1 disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load."
"PA"	19107206	5	"Syndecan 2"	275	285	"Genes & Molecular Sequences"	"HIV"	61	64	"Diseases & Disorders"	"Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene)."
"FA"	19107206	4	"rs2395029"	80	89	"SNP & Sequence variations"	"HIV"	189	192	"Diseases & Disorders"	"Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers."
"PA"	19107206	1	"HLA"	54	57	"Genes & Molecular Sequences"	"HIV-1 disease"	24	37	"Diseases & Disorders"	"Previous studies of the HIV-1 disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load."
"FA"	19107206	5	"rs2575735"	253	262	"SNP & Sequence variations"	"HIV"	61	64	"Diseases & Disorders"	"Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene)."
"FA"	19107206	4	"MHC"	69	72	"Genes & Molecular Sequences"	"HIV"	189	192	"Diseases & Disorders"	"Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers."
"FA"	19107206	4	"rs3093662"	118	127	"SNP & Sequence variations"	"HIV"	189	192	"Diseases & Disorders"	"Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers."
"FA"	19107206	6	"MHC"	35	38	"Genes & Molecular Sequences"	"HIV"	73	76	"Diseases & Disorders"	"Our data provide evidence that the MHC controls both HIV replication and HIV reservoir."
"FA"	19107206	4	"rs12198173"	103	113	"SNP & Sequence variations"	"HIV"	189	192	"Diseases & Disorders"	"Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers."
"FA"	19107206	5	"rs6503919"	168	177	"SNP & Sequence variations"	"HIV"	61	64	"Diseases & Disorders"	"Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene)."
"PA"	18508791	5	"SH3TC2"	74	80	"Genes & Molecular Sequences"	"5q- syndrome"	35	47	"Diseases & Disorders"	"The commonly deleted region of the 5q- syndrome extends between the genes SH3TC2 (proximal boundary) and GLRA1 (distal boundary) and measures 2.9 Mb."
"PA"	18508791	5	"GLRA1"	105	110	"Genes & Molecular Sequences"	"5q- syndrome"	35	47	"Diseases & Disorders"	"The commonly deleted region of the 5q- syndrome extends between the genes SH3TC2 (proximal boundary) and GLRA1 (distal boundary) and measures 2.9 Mb."
"PA"	19106306	2	"HC gp-39"	76	84	"Genes & Molecular Sequences"	"inflammatory and allergic diseases"	121	155	"Diseases & Disorders"	"Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or HC gp-39, is involved in the pathogenesis of inflammatory and allergic diseases."
"PA"	19106306	12	"g.-247C/T"	40	49	"SNP & Sequence variations"	"atopy"	124	129	"Diseases & Disorders"	"These results strongly suggest that the g.-247C/T polymorphism in the CHI3L1 promoter region is associated with the risk of atopy."
"PA"	19106306	0	"chitinase 3-like 1"	44	62	"Genes & Molecular Sequences"	"atopy"	82	87	"Diseases & Disorders"	"Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy."
"PA"	19106306	7	"IVS7+82C/T"	125	135	"SNP & Sequence variations"	"atopy"	233	238	"Diseases & Disorders"	"In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy."
"PA"	19106306	7	"rs10399805"	93	103	"SNP & Sequence variations"	"atopy"	233	238	"Diseases & Disorders"	"In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy."
"PA"	19106306	12	"CHI3L1"	70	76	"Genes & Molecular Sequences"	"atopy"	124	129	"Diseases & Disorders"	"These results strongly suggest that the g.-247C/T polymorphism in the CHI3L1 promoter region is associated with the risk of atopy."
"PA"	19106306	3	"CHI3L1"	28	34	"Genes & Molecular Sequences"	"atopic"	43	49	"Diseases & Disorders"	"The genetic contribution of CHI3L1 gene to atopic susceptibility was investigated using an integrated population genetic and molecular analysis."
"PA"	19106306	4	"CHI3L1"	22	28	"Genes & Molecular Sequences"	"atopy"	90	95	"Diseases & Disorders"	"Genetic variations in CHI3L1 were identified and genotyped in 295 unrelated patients with atopy and 180 control subjects."
"PA"	19106306	7	"CHI3L1"	188	194	"Genes & Molecular Sequences"	"atopy"	233	238	"Diseases & Disorders"	"In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy."
"PA"	19106306	7	"rs2275353"	162	171	"SNP & Sequence variations"	"atopy"	233	238	"Diseases & Disorders"	"In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy."
"PA"	19106306	7	"g.-247C/T"	46	55	"SNP & Sequence variations"	"atopy"	233	238	"Diseases & Disorders"	"In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy."
"FA"	17898177	4	"CEP290/NPHP6"	61	73	"Genes & Molecular Sequences"	"Leber congenital amaurosis"	163	189	"Diseases & Disorders"	"In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy."
"FA"	17898177	0	"CEP290"	12	18	"Genes & Molecular Sequences"	"anosmia"	45	52	"Diseases & Disorders"	"Hypomorphic CEP290/NPHP6 mutations result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons."
"PA"	17898177	4	"CEP290/NPHP6"	61	73	"Genes & Molecular Sequences"	"Meckel syndromes"	105	121	"Diseases & Disorders"	"In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy."
"PA"	17898177	4	"CEP290/NPHP6"	61	73	"Genes & Molecular Sequences"	"Joubert"	93	100	"Diseases & Disorders"	"In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy."
"SA"	19104434	0	"MBL promoter haplotype"	26	48	"Genes & Molecular Sequences"	"BOS"	91	94	"Diseases & Disorders"	"Association between donor MBL promoter haplotype and graft survival and the development of BOS after lung transplantation."
"NA"	18297189	9	"epsilon4"	69	77	"SNP & Sequence variations"	"hypertension"	113	125	"Diseases & Disorders"	"Compared with the epsilon3 homozygotes, neither the epsilon2 nor the epsilon4 carrier status was associated with hypertension (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively)."
"NA"	18297189	9	"epsilon2"	52	60	"SNP & Sequence variations"	"hypertension"	113	125	"Diseases & Disorders"	"Compared with the epsilon3 homozygotes, neither the epsilon2 nor the epsilon4 carrier status was associated with hypertension (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively)."
"PA"	18297189	1	"Apolipoprotein E"	0	16	"Genes & Molecular Sequences"	"arterial hypertension"	91	112	"Diseases & Disorders"	"Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with arterial hypertension is controversial."
"NA"	18297189	11	"ApoE"	52	56	"Genes & Molecular Sequences"	"prevalent hypertension"	89	111	"Diseases & Disorders"	"This study provides epidemiologic evidence that the ApoE genotype is not associated with prevalent hypertension in old age."
"PA"	19099048	4	"MMP"	180	183	"Genes & Molecular Sequences"	"TAA"	673	676	"Diseases & Disorders"	"Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease."
"PA"	19099048	4	"matrix metalloproteinase"	154	178	"Genes & Molecular Sequences"	"TAA"	673	676	"Diseases & Disorders"	"Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease."
"FA"	19092295	4	"LIGIV"	282	287	"Genes & Molecular Sequences"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"FA"	19092295	4	"PRO72ARG"	555	563	"SNP & Sequence variations"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"PA"	19092295	0	"RAD52 polymorphisms"	0	19	"Genes & Molecular Sequences"	"papillary thyroid cancer"	53	77	"Diseases & Disorders"	"RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population."
"PA"	19092295	4	"Tp53"	565	569	"Genes & Molecular Sequences"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"FA"	19092295	4	"ARG280HIS"	632	641	"SNP & Sequence variations"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"FA"	19092295	4	"GLN221GLU"	494	503	"SNP & Sequence variations"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"PA"	19092295	4	"XRCC1"	615	620	"Genes & Molecular Sequences"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"SA"	19092295	8	"RAD52 GLN221GLU"	40	55	"SNP & Sequence variations"	"papillary thyroid cancer"	123	147	"Diseases & Disorders"	"Of the 21 loci screened, RAD52 2259 and RAD52 GLN221GLU may be of importance to disease process and may be associated with papillary thyroid cancer risk in Saudi Arabian population."
"FA"	19092295	4	"THR241MET"	432	441	"SNP & Sequence variations"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"FA"	19092295	4	"PRO231SER"	305	314	"SNP & Sequence variations"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"FA"	19092295	4	"ARG399GLN"	643	652	"SNP & Sequence variations"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"PA"	19092295	4	"XRCC7"	356	361	"Genes & Molecular Sequences"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"FA"	19092295	4	"ARG559GLN"	654	663	"SNP & Sequence variations"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"FA"	19092295	4	"15455419A>G"	466	477	"SNP & Sequence variations"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"PA"	19092295	5	"RAD52 GLN221GLU"	0	15	"SNP & Sequence variations"	"thyroid cancer"	125	139	"Diseases & Disorders"	"RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58]."
"PA"	19092295	4	"RAD51"	443	448	"Genes & Molecular Sequences"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"PA"	19092295	4	"XRCC3"	413	418	"Genes & Molecular Sequences"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"FA"	19092295	4	"TRP46TER"	316	324	"SNP & Sequence variations"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"FA"	19092295	4	"LIGlV ASP62HIS"	289	303	"SNP & Sequence variations"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"PA"	19092295	4	"XRCC4"	327	332	"Genes & Molecular Sequences"	"papillary thyroid cancer"	38	62	"Diseases & Disorders"	"Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN."
"PA"	18479189	2	"GPx1"	127	131	"Genes & Molecular Sequences"	"colitis"	94	101	"Diseases & Disorders"	"An anti-inflammatory and anticarcinogenic potential has been inferred from the development of colitis and intestinal cancer in GPx1 and GPx2 double knockout mice."
"PA"	18479189	2	"GPx1"	127	131	"Genes & Molecular Sequences"	"intestinal cancer"	106	123	"Diseases & Disorders"	"An anti-inflammatory and anticarcinogenic potential has been inferred from the development of colitis and intestinal cancer in GPx1 and GPx2 double knockout mice."
"SA"	18479189	11	"GPx2"	6	10	"Genes & Molecular Sequences"	"carcinogenesis"	118	132	"Diseases & Disorders"	"Thus, GPx2 may prevent undue responses to inflammatory stimuli and, in consequence, inflammation-driven initiation of carcinogenesis."
"PA"	18479189	4	"COX-2"	22	27	"Genes & Molecular Sequences"	"inflammation"	71	83	"Diseases & Disorders"	"In contrast, enhanced COX-2 expression is consistently associated with inflammation."
"PA"	18479189	2	"GPx2"	136	140	"Genes & Molecular Sequences"	"intestinal cancer"	106	123	"Diseases & Disorders"	"An anti-inflammatory and anticarcinogenic potential has been inferred from the development of colitis and intestinal cancer in GPx1 and GPx2 double knockout mice."
"PA"	18479189	2	"GPx2"	136	140	"Genes & Molecular Sequences"	"colitis"	94	101	"Diseases & Disorders"	"An anti-inflammatory and anticarcinogenic potential has been inferred from the development of colitis and intestinal cancer in GPx1 and GPx2 double knockout mice."
"FA"	18804983	10	"CARD15"	96	102	"Genes & Molecular Sequences"	"CD"	164	166	"Diseases & Disorders"	"For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A."
"PA"	18804983	10	"G908R"	123	128	"SNP & Sequence variations"	"CD"	164	166	"Diseases & Disorders"	"For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A."
"PA"	18804983	10	"L1007fsinsC"	133	144	"SNP & Sequence variations"	"CD"	164	166	"Diseases & Disorders"	"For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A."
"PA"	18804983	10	"TNF-alpha-G308A"	207	222	"SNP & Sequence variations"	"CD"	164	166	"Diseases & Disorders"	"For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A."
"NA"	18804983	9	"NF kappaB -94ATTG"	4	21	"SNP & Sequence variations"	"CD"	62	64	"Diseases & Disorders"	"The NF kappaB -94ATTG variants was found to be irrelevant for CD."
"PA"	18804983	10	"FcGIIIA G559T"	189	202	"SNP & Sequence variations"	"CD"	164	166	"Diseases & Disorders"	"For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A."
"PA"	19111066	3	"C-allele of PKLR rs3020781"	4	30	"SNP & Sequence variations"	"type 2 diabetes"	108	123	"Diseases & Disorders"	"The C-allele of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively."
"NA"	19111066	11	"PKLR"	18	22	"Genes & Molecular Sequences"	"diabetes-related quantitative metabolic phenotypes"	99	149	"Diseases & Disorders"	"Additionally, the PKLR and the NOS1AP genotypes were demonstrated not to have a major influence on diabetes-related quantitative metabolic phenotypes."
"FA"	19111066	12	"NOS1AP rs7538490"	75	91	"Genes & Molecular Sequences"	"overweight"	113	123	"Diseases & Disorders"	"We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes."
"PA"	19111066	3	"PKLR"	16	20	"Genes & Molecular Sequences"	"type 2 diabetes"	108	123	"Diseases & Disorders"	"The C-allele of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively."
"NA"	19111066	12	"PKLR rs3020781"	56	70	"Genes & Molecular Sequences"	"type 2 diabetes"	96	111	"Diseases & Disorders"	"We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes."
"NA"	19111066	9	"rs3020781"	63	72	"SNP & Sequence variations"	"type 2 diabetes"	46	61	"Diseases & Disorders"	"No significant associations were observed for type 2 diabetes (rs3020781: pAF = 0.49, OR = 1.02 [0.96-1.10]; rs7538490: pAF = 0.84, OR = 0.99 [0.93-1.06])."
"FA"	19111066	0	"NOS1AP rs7538490"	47	63	"Genes & Molecular Sequences"	"obesity"	97	104	"Diseases & Disorders"	"Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits."
"FA"	19111066	0	"NOS1AP rs7538490"	47	63	"Genes & Molecular Sequences"	"overweight"	85	95	"Diseases & Disorders"	"Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits."
"FA"	19111066	12	"NOS1AP rs7538490"	75	91	"Genes & Molecular Sequences"	"obesity"	125	132	"Diseases & Disorders"	"We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes."
"NA"	19111066	0	"PKLR rs3020781"	28	42	"Genes & Molecular Sequences"	"type 2 diabetes"	68	83	"Diseases & Disorders"	"Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits."
"PA"	19111066	3	"T-allele of NOS1AP rs7538490"	39	67	"SNP & Sequence variations"	"type 2 diabetes"	108	123	"Diseases & Disorders"	"The C-allele of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively."
"NA"	19111066	0	"NOS1AP rs7538490"	47	63	"Genes & Molecular Sequences"	"type 2 diabetes"	68	83	"Diseases & Disorders"	"Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits."
"NA"	19111066	12	"NOS1AP rs7538490"	75	91	"Genes & Molecular Sequences"	"type 2 diabetes"	96	111	"Diseases & Disorders"	"We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes."
"NA"	19111066	11	"NOS1AP"	31	37	"Genes & Molecular Sequences"	"diabetes-related quantitative metabolic phenotypes"	99	149	"Diseases & Disorders"	"Additionally, the PKLR and the NOS1AP genotypes were demonstrated not to have a major influence on diabetes-related quantitative metabolic phenotypes."
"NA"	19111066	9	"rs7538490"	109	118	"SNP & Sequence variations"	"type 2 diabetes"	46	61	"Diseases & Disorders"	"No significant associations were observed for type 2 diabetes (rs3020781: pAF = 0.49, OR = 1.02 [0.96-1.10]; rs7538490: pAF = 0.84, OR = 0.99 [0.93-1.06])."
"PA"	19111066	3	"NOS1AP"	51	57	"Genes & Molecular Sequences"	"type 2 diabetes"	108	123	"Diseases & Disorders"	"The C-allele of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively."
"FA"	19111066	12	"PKLR rs3020781"	56	70	"Genes & Molecular Sequences"	"obesity"	125	132	"Diseases & Disorders"	"We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes."
"FA"	19111066	0	"PKLR rs3020781"	28	42	"Genes & Molecular Sequences"	"overweight"	85	95	"Diseases & Disorders"	"Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits."
"FA"	19111066	0	"PKLR rs3020781"	28	42	"Genes & Molecular Sequences"	"obesity"	97	104	"Diseases & Disorders"	"Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits."
"PA"	18202791	2	"COX-2"	214	219	"Genes & Molecular Sequences"	"oral leukoplakia"	105	121	"Diseases & Disorders"	"Although COX-2 is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively little research has compared the effects of various COX-2 inhibitors (celecoxib, NS-398, nimesulide and meloxicam)."
"PA"	18202791	2	"COX-2"	214	219	"Genes & Molecular Sequences"	"squamous cell carcinoma"	126	149	"Diseases & Disorders"	"Although COX-2 is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively little research has compared the effects of various COX-2 inhibitors (celecoxib, NS-398, nimesulide and meloxicam)."
"FA"	18202791	8	"COX-2"	158	163	"Genes & Molecular Sequences"	"OSCC"	71	75	"Diseases & Disorders"	"Taken together, celecoxib is a good therapeutic candidate for treating OSCC through the suppression of cell proliferation and the induction of apoptosis in a COX-2 independent manner."
"PA"	19114657	0	"STK39"	58	63	"Genes & Molecular Sequences"	"hypertension"	69	81	"Diseases & Disorders"	"From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene."
"PA"	17618837	1	"rs11209026"	84	94	"SNP & Sequence variations"	"CD"	166	168	"Diseases & Disorders"	"Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults."
"PA"	17618837	1	"IL23R"	132	137	"Genes & Molecular Sequences"	"Crohn's disease"	149	164	"Diseases & Disorders"	"Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults."
"FA"	17618837	1	"IL23R"	132	137	"Genes & Molecular Sequences"	"CD"	166	168	"Diseases & Disorders"	"Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults."
"PA"	17618837	1	"rs11209026"	84	94	"SNP & Sequence variations"	"Crohn's disease"	149	164	"Diseases & Disorders"	"Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults."
"FA"	17618837	3	"IL23R"	201	206	"Genes & Molecular Sequences"	"CD"	92	94	"Diseases & Disorders"	"By using data from our ongoing genome-wide association study in our cohort of 142 pediatric CD patients and 281 matched controls, we investigated the association of the previously reported SNPs at the IL23R locus with the childhood form of this disease."
"PA"	17618837	9	"variants in the IL23R"	9	30	"Genes & Molecular Sequences"	"CD"	74	76	"Diseases & Disorders"	"As such, variants in the IL23R gene confer a similar magnitude of risk of CD to children as for their adult counterparts."
"PA"	17618837	8	"IL23R variant"	14	27	"Genes & Molecular Sequences"	"inflammatory bowel disease"	124	150	"Diseases & Disorders"	"The OR of the IL23R variant in our pediatric study is highly comparable with that reported previously in a non-Jewish adult inflammatory bowel disease case-control cohort (OR, 0.26)."
"PA"	17618837	0	"interleukin-23 receptor"	31	54	"Genes & Molecular Sequences"	"pediatric Crohn's disease"	83	108	"Diseases & Disorders"	"Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease."
"PA"	19104506	0	"interleukin-1 receptor antagonist"	18	51	"Genes & Molecular Sequences"	"colorectal cancer"	102	119	"Diseases & Disorders"	"Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer."
"SA"	19104506	1	"IL-1RA"	39	45	"Genes & Molecular Sequences"	"metastasis"	100	110	"Diseases & Disorders"	"The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis."
"SA"	19104506	1	"IL-1RA"	39	45	"Genes & Molecular Sequences"	"tumor angiogenesis"	81	99	"Diseases & Disorders"	"The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis."
"FA"	19104506	3	"rs579543 T/T"	162	174	"SNP & Sequence variations"	"metastatic colorectal cancer"	29	57	"Diseases & Disorders"	"A total of 180 patients with metastatic colorectal cancer were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers)."
"PA"	19104506	3	"IL-1RA"	83	89	"Genes & Molecular Sequences"	"metastatic colorectal cancer"	29	57	"Diseases & Disorders"	"A total of 180 patients with metastatic colorectal cancer were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers)."
"FA"	19104506	3	"rs4251961 T/T"	145	158	"SNP & Sequence variations"	"metastatic colorectal cancer"	29	57	"Diseases & Disorders"	"A total of 180 patients with metastatic colorectal cancer were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers)."
"SA"	19105801	2	"VDR"	20	23	"Genes & Molecular Sequences"	"MM"	152	154	"Diseases & Disorders"	"Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population."
"SA"	19105801	2	"VDR"	20	23	"Genes & Molecular Sequences"	"sporadic breast cancer"	101	123	"Diseases & Disorders"	"Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population."
"SA"	19105801	2	"VDR"	20	23	"Genes & Molecular Sequences"	"malignant melanoma"	132	150	"Diseases & Disorders"	"Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population."
"SA"	19105801	7	"rs731236"	23	31	"SNP & Sequence variations"	"BC"	86	88	"Diseases & Disorders"	"The synonymous variant rs731236 (TaqI) appeared to be associated with protection from BC (OR = 0.80, 95%CI = 0.64-0.99; p = 0.047)."
"SA"	19105801	2	"VDR"	20	23	"Genes & Molecular Sequences"	"BC"	125	127	"Diseases & Disorders"	"Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population."
"PA"	19105801	2	"VDR"	20	23	"Genes & Molecular Sequences"	"cancer"	49	55	"Diseases & Disorders"	"Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population."
"SA"	19105801	10	"SNPs in the VDR"	45	60	"Genes & Molecular Sequences"	"MM"	212	214	"Diseases & Disorders"	"In summary, we observed associations between SNPs in the VDR gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM."
"FA"	19105801	6	"rs2228570"	65	74	"SNP & Sequence variations"	"BC"	120	122	"Diseases & Disorders"	"An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, Met1Thr) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036)."
"PA"	19105801	6	"rs10735810"	76	86	"SNP & Sequence variations"	"BC"	120	122	"Diseases & Disorders"	"An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, Met1Thr) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036)."
"PA"	19105801	10	"SNPs in the VDR"	45	60	"Genes & Molecular Sequences"	"BC"	70	72	"Diseases & Disorders"	"In summary, we observed associations between SNPs in the VDR gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM."
"PA"	19105843	1	"INSIG2"	29	35	"Genes & Molecular Sequences"	"obesity"	136	143	"Diseases & Disorders"	"A common SNP upstream of the INSIG2 gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts."
"FA"	19105843	1	"rs7566605"	42	51	"SNP & Sequence variations"	"obesity"	136	143	"Diseases & Disorders"	"A common SNP upstream of the INSIG2 gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts."
"PA"	19105843	10	"INSIG2 rs7566605"	108	124	"Genes & Molecular Sequences"	"obesity"	96	103	"Diseases & Disorders"	"This supports and extends the original finding that there is an association between measures of obesity and INSIG2 rs7566605 and further implicates this polymorphism in fat regulation."
"PA"	19105843	9	"INSIG2 rs7566605"	26	42	"Genes & Molecular Sequences"	"adiposity"	92	101	"Diseases & Disorders"	"Our results show that the INSIG2 rs7566605 polymorphism underlies variation in subcutaneous adiposity in young adult women and suppresses the positive effects of resistance training on men."
"PA"	19101508	2	"HCNPpp"	51	57	"Genes & Molecular Sequences"	"AD"	213	215	"Diseases & Disorders"	"Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the pathogenesis of AD."
"PA"	19101508	2	"HCNPpp"	51	57	"Genes & Molecular Sequences"	"Alzheimer's disease"	118	137	"Diseases & Disorders"	"Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the pathogenesis of AD."
"FA"	19101508	3	"HCNPpp"	90	96	"Genes & Molecular Sequences"	"AD"	200	202	"Diseases & Disorders"	"To clarify the involvement of gene variations in the promoter region of the gene encoding HCNPpp in this mRNA reduction, we analyzed DNA polymorphisms or mutations within this gene promoter region in AD patients by direct sequencing."
"PA"	19101508	2	"HCNP"	183	187	"Genes & Molecular Sequences"	"AD"	213	215	"Diseases & Disorders"	"Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the pathogenesis of AD."
"PA"	19101508	2	"HCNP"	183	187	"Genes & Molecular Sequences"	"Alzheimer's disease"	118	137	"Diseases & Disorders"	"Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the pathogenesis of AD."
"PA"	19107338	2	"K121Q"	4	9	"SNP & Sequence variations"	"insulin resistance"	194	212	"Diseases & Disorders"	"The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity."
"PA"	19107338	2	"K121Q"	4	9	"SNP & Sequence variations"	"obesity"	217	224	"Diseases & Disorders"	"The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity."
"FA"	19107338	0	"ectonucleotide pyrophosphatase/phosphodiesterase 1"	41	91	"Genes & Molecular Sequences"	"hepatitis C virus infection"	97	124	"Diseases & Disorders"	"Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan."
"FA"	19107338	8	"rs7566605"	17	26	"SNP & Sequence variations"	"hepatitis C"	60	71	"Diseases & Disorders"	"In contrast, the rs7566605 genotype was not associated with hepatitis C viremia or with the HCV core antigen level."
"FA"	19107338	9	"K121Q"	4	9	"SNP & Sequence variations"	"hepatitis C"	50	61	"Diseases & Disorders"	"The K121Q variant of ENPP1 may be associated with hepatitis C viremia and core antigen levels in HCV carriers."
"FA"	19107338	2	"ENPP)-1"	80	87	"Genes & Molecular Sequences"	"obesity"	217	224	"Diseases & Disorders"	"The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity."
"FA"	19107338	2	"ENPP)-1"	80	87	"Genes & Molecular Sequences"	"insulin resistance"	194	212	"Diseases & Disorders"	"The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity."
"PA"	19107338	3	"K121Q"	32	37	"SNP & Sequence variations"	"HCV infection"	128	141	"Diseases & Disorders"	"This study examined whether the K121Q polymorphism in ENPP1 or the rs7566605 genotype is associated with the clinical course of HCV infection."
"PA"	19107338	3	"rs7566605"	67	76	"SNP & Sequence variations"	"HCV infection"	128	141	"Diseases & Disorders"	"This study examined whether the K121Q polymorphism in ENPP1 or the rs7566605 genotype is associated with the clinical course of HCV infection."
"PA"	19107338	3	"ENPP1"	54	59	"Genes & Molecular Sequences"	"HCV infection"	128	141	"Diseases & Disorders"	"This study examined whether the K121Q polymorphism in ENPP1 or the rs7566605 genotype is associated with the clinical course of HCV infection."
"PA"	19107338	2	"rs7566605"	101	110	"SNP & Sequence variations"	"insulin resistance"	194	212	"Diseases & Disorders"	"The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity."
"PA"	19107338	9	"ENPP1"	21	26	"Genes & Molecular Sequences"	"hepatitis C"	50	61	"Diseases & Disorders"	"The K121Q variant of ENPP1 may be associated with hepatitis C viremia and core antigen levels in HCV carriers."
"PA"	19107338	2	"rs7566605"	101	110	"SNP & Sequence variations"	"obesity"	217	224	"Diseases & Disorders"	"The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity."
"PA"	19110537	6	"IL-10"	175	180	"Genes & Molecular Sequences"	"Mycobacterium leprae antigens"	90	119	"Diseases & Disorders"	"Finally, we tested IL-10 production in peripheral blood mononuclear cells stimulated with Mycobacterium leprae antigens and found that -819T carriers produced lower levels of IL-10 when compared with non-carriers."
"SA"	19110537	7	"IL-10"	54	59	"Genes & Molecular Sequences"	"leprosy"	166	173	"Diseases & Disorders"	"Taken together, these data suggest that low levels of IL-10 during the disease outcome can drive patients to a chronic and unprotective response that culminates with leprosy."
"PA"	19110537	0	"interleukin-10 promoter single-nucleotide polymorphisms"	52	107	"Genes & Molecular Sequences"	"leprosy"	150	157	"Diseases & Disorders"	"Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for -819C/T in leprosy susceptibility."
"PA"	19110537	3	"IL-10"	221	226	"Genes & Molecular Sequences"	"leprosy"	247	254	"Diseases & Disorders"	"Here, we combined a case-control study (374 patients and 380 controls), with meta-analysis (5 studies; 2702 individuals) and biological study to test the epidemiological and physiological relevance of the interleukin-10 (IL-10) genetic markers in leprosy."
"PA"	19110537	0	"-819C/T"	139	146	"SNP & Sequence variations"	"leprosy"	150	157	"Diseases & Disorders"	"Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for -819C/T in leprosy susceptibility."
"PA"	19110537	5	"-819T"	103	108	"SNP & Sequence variations"	"leprosy"	119	126	"Diseases & Disorders"	"Haplotypes combining promoter single-nucleotide polymorphisms also implicated a haplotype carrying the -819T allele in leprosy susceptibility (odds ratio (OR)=1.40; P=0.01)."
"FA"	19110537	6	"-819T"	135	140	"SNP & Sequence variations"	"Mycobacterium leprae antigens"	90	119	"Diseases & Disorders"	"Finally, we tested IL-10 production in peripheral blood mononuclear cells stimulated with Mycobacterium leprae antigens and found that -819T carriers produced lower levels of IL-10 when compared with non-carriers."
"PA"	19110537	4	"-819T"	21	26	"SNP & Sequence variations"	"leprosy"	53	60	"Diseases & Disorders"	"We observed that the -819T allele is associated with leprosy susceptibility either in the case-control or in the meta-analysis studies."
"FA"	19098994	2	"LOXL1 polymorphisms"	15	34	"Genes & Molecular Sequences"	"POAG"	94	98	"Diseases & Disorders"	"The implicated LOXL1 polymorphisms have not been associated with primary open-angle glaucoma (POAG)."
"NA"	19098994	12	"rs3825942"	34	43	"SNP & Sequence variations"	"POAG"	85	89	"Diseases & Disorders"	"Individual LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, were not associated with POAG in the Chinese population."
"PA"	19098994	1	"LOXL1"	34	39	"Genes & Molecular Sequences"	"exfoliation glaucoma"	74	94	"Diseases & Disorders"	"The lysyl oxidase-like protein 1 (LOXL1) gene is strongly associated with exfoliation glaucoma, which is very rare in the Chinese population."
"SA"	19098994	14	"rs1048661"	46	55	"SNP & Sequence variations"	"exfoliation syndrome"	130	150	"Diseases & Disorders"	"The low frequencies of the at-risk alleles at rs1048661 and rs2165241 may be one of the factors that led to the low prevalence of exfoliation syndrome in the general populations of the Chinese."
"NA"	19098994	12	"rs2165241"	49	58	"SNP & Sequence variations"	"POAG"	85	89	"Diseases & Disorders"	"Individual LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, were not associated with POAG in the Chinese population."
"SA"	19098994	14	"rs2165241"	60	69	"SNP & Sequence variations"	"exfoliation syndrome"	130	150	"Diseases & Disorders"	"The low frequencies of the at-risk alleles at rs1048661 and rs2165241 may be one of the factors that led to the low prevalence of exfoliation syndrome in the general populations of the Chinese."
"FA"	19098994	12	"LOXL1"	11	16	"Genes & Molecular Sequences"	"POAG"	85	89	"Diseases & Disorders"	"Individual LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, were not associated with POAG in the Chinese population."
"NA"	19098994	12	"rs1048661"	23	32	"SNP & Sequence variations"	"POAG"	85	89	"Diseases & Disorders"	"Individual LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, were not associated with POAG in the Chinese population."
"PA"	19366086	0	"A1298C mutations of the MTHFR"	42	71	"Genes & Molecular Sequences"	"hyperhomocysteinemia"	90	110	"Diseases & Disorders"	"Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age."
"FA"	19366086	0	"C677T"	32	37	"SNP & Sequence variations"	"hyperhomocysteinemia"	90	110	"Diseases & Disorders"	"Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age."
"FA"	19094116	7	"NOD2"	66	70	"Genes & Molecular Sequences"	"CD"	3	5	"Diseases & Disorders"	"In CD patients, TLR-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms."
"FA"	19094116	12	"GM-CSF"	150	156	"Genes & Molecular Sequences"	"CD"	95	97	"Diseases & Disorders"	"The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent disease risk factor."
"FA"	19094116	4	"NOD2 SNP"	9	17	"Genes & Molecular Sequences"	"CD"	31	33	"Diseases & Disorders"	"Based on NOD2 SNP analyses, 41 CD patients and 12 healthy controls were studied."
"PA"	19094116	0	"Toll-like receptor"	0	18	"Genes & Molecular Sequences"	"Crohn's disease"	101	116	"Diseases & Disorders"	"Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways."
"PA"	19094116	0	"granulocyte-macrophage colony-stimulating factor"	27	75	"Genes & Molecular Sequences"	"Crohn's disease"	101	116	"Diseases & Disorders"	"Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways."
"FA"	19094116	8	"TLR"	48	51	"Genes & Molecular Sequences"	"CD"	162	164	"Diseases & Disorders"	"Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in CD patients."
"FA"	19094116	11	"GM-CSF"	26	32	"Genes & Molecular Sequences"	"CD"	0	2	"Diseases & Disorders"	"CD patients have impaired GM-CSF secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion."
"FA"	19094116	11	"TNF-alpha"	146	155	"Genes & Molecular Sequences"	"CD"	0	2	"Diseases & Disorders"	"CD patients have impaired GM-CSF secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion."
"PA"	19094116	2	"NOD2"	151	155	"Genes & Molecular Sequences"	"Crohn's disease"	214	229	"Diseases & Disorders"	"Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (CD)."
"PA"	19094116	2	"NOD2"	151	155	"Genes & Molecular Sequences"	"CD"	231	233	"Diseases & Disorders"	"Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (CD)."
"FA"	19094116	10	"GM-CSF"	72	78	"Genes & Molecular Sequences"	"CD"	0	2	"Diseases & Disorders"	"CD patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands."
"PA"	19094116	12	"NOD2"	189	193	"Genes & Molecular Sequences"	"CD"	95	97	"Diseases & Disorders"	"The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent disease risk factor."
"PA"	19094116	11	"NOD2"	112	116	"Genes & Molecular Sequences"	"CD"	0	2	"Diseases & Disorders"	"CD patients have impaired GM-CSF secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion."
"PA"	19094116	2	"nucleotide oligomerization domain 2"	157	192	"Genes & Molecular Sequences"	"CD"	231	233	"Diseases & Disorders"	"Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (CD)."
"PA"	19094116	2	"nucleotide oligomerization domain 2"	157	192	"Genes & Molecular Sequences"	"Crohn's disease"	214	229	"Diseases & Disorders"	"Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (CD)."
"FA"	19094116	7	"GM-CSF"	28	34	"Genes & Molecular Sequences"	"CD"	3	5	"Diseases & Disorders"	"In CD patients, TLR-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms."
"FA"	19094116	0	"nucleotide oligomerization domain 2"	120	155	"Genes & Molecular Sequences"	"Crohn's disease"	101	116	"Diseases & Disorders"	"Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways."
"PA"	19094116	8	"NOD2"	100	104	"Genes & Molecular Sequences"	"CD"	162	164	"Diseases & Disorders"	"Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in CD patients."
"PA"	19094116	7	"TLR"	16	19	"Genes & Molecular Sequences"	"CD"	3	5	"Diseases & Disorders"	"In CD patients, TLR-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms."
"PA"	18470928	1	"IL-23"	4	9	"Genes & Molecular Sequences"	"chronic mucosal inflammation"	61	89	"Diseases & Disorders"	"The IL-23 pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the inflammatory bowel diseases."
"SA"	18470928	0	"IL23R haplotypes"	0	16	"Genes & Molecular Sequences"	"Crohn's disease"	66	81	"Diseases & Disorders"	"IL23R haplotypes provide a large population attributable risk for Crohn's disease."
"PA"	18470928	2	"IL23R R381Q"	150	161	"SNP & Sequence variations"	"Crohn's disease"	102	117	"Diseases & Disorders"	"Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (CD) risk in general and of the IL23R R381Q variant in particular."
"SA"	18470928	8	"R381Q"	157	162	"SNP & Sequence variations"	"CD"	74	76	"Diseases & Disorders"	"These observations suggest that IL23R makes a substantial contribution to CD susceptibility, larger than that estimated from the population frequency of the R381Q variant."
"PA"	18470928	2	"IL23R R381Q"	150	161	"SNP & Sequence variations"	"CD"	119	121	"Diseases & Disorders"	"Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (CD) risk in general and of the IL23R R381Q variant in particular."
"PA"	18470928	1	"IL-23"	4	9	"Genes & Molecular Sequences"	"inflammatory bowel diseases"	102	129	"Diseases & Disorders"	"The IL-23 pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the inflammatory bowel diseases."
"PA"	18470928	2	"IL23R"	92	97	"Genes & Molecular Sequences"	"CD"	119	121	"Diseases & Disorders"	"Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (CD) risk in general and of the IL23R R381Q variant in particular."
"SA"	18470928	8	"IL23R"	32	37	"Genes & Molecular Sequences"	"CD"	74	76	"Diseases & Disorders"	"These observations suggest that IL23R makes a substantial contribution to CD susceptibility, larger than that estimated from the population frequency of the R381Q variant."
"PA"	18470928	2	"IL23R"	92	97	"Genes & Molecular Sequences"	"Crohn's disease"	102	117	"Diseases & Disorders"	"Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (CD) risk in general and of the IL23R R381Q variant in particular."
"FA"	18470928	4	"IL23R"	99	104	"Genes & Molecular Sequences"	"CD"	12	14	"Diseases & Disorders"	"In all, 763 CD subjects and 254 controls were genotyped for single nucleotide polymorphisms in the IL23R gene using Illumina and ABI methods."
"PA"	18846214	0	"3q26"	99	103	"Genes & Molecular Sequences"	"myopia"	46	52	"Diseases & Disorders"	"Identification and replication of three novel myopia common susceptibility gene loci on chromosome 3q26 using linkage and linkage disequilibrium mapping."
"PA"	17592645	15	"c.+119A > T in the 3'-UTR"	25	50	"SNP & Sequence variations"	"ASD type II"	67	78	"Diseases & Disorders"	"In a family, we observed c.+119A > T in the 3'-UTR associated with ASD type II."
"PA"	19029774	0	"growth hormone-releasing hormone receptor messenger ribonucleic acid"	13	81	"Genes & Molecular Sequences"	"growth hormone-secreting pituitary adenoma"	96	138	"Diseases & Disorders"	"Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation."
"PA"	19029774	2	"GHRH receptor"	18	31	"Genes & Molecular Sequences"	"GH-secreting pituitary adenoma"	111	141	"Diseases & Disorders"	"The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human GH-secreting pituitary adenoma cells."
"PA"	19029774	10	"GHRH"	257	261	"Genes & Molecular Sequences"	"GH-secreting pituitary adenoma"	78	108	"Diseases & Disorders"	"These results suggest that gsp mutations up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling."
"PA"	19029774	2	"GHRH"	56	60	"Genes & Molecular Sequences"	"GH-secreting pituitary adenoma"	111	141	"Diseases & Disorders"	"The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human GH-secreting pituitary adenoma cells."
"PA"	19029774	10	"GHRHR mRNA"	195	205	"Genes & Molecular Sequences"	"GH-secreting pituitary adenoma"	78	108	"Diseases & Disorders"	"These results suggest that gsp mutations up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling."
"PA"	19101572	1	"Cdc6"	0	4	"Genes & Molecular Sequences"	"carcinogenesis"	47	61	"Diseases & Disorders"	"Cdc6 play crucial roles in DNA replication and carcinogenesis."
"PA"	19101572	8	"Cdc6 G1321A"	45	56	"Genes & Molecular Sequences"	"cancer"	107	113	"Diseases & Disorders"	"Our data provide the first evidence that the Cdc6 G1321A polymorphism is associated with decreased risk of cancer."
"PA"	18630531	4	"VEGF"	91	95	"Genes & Molecular Sequences"	"breast cancer"	36	49	"Diseases & Disorders"	"To assess clinical significance, 93 breast cancer lesions were evaluated for expression of VEGF and VEGFR-1 by immunohistochemistry."
"PA"	18630531	4	"VEGFR-1"	100	107	"Genes & Molecular Sequences"	"breast cancer"	36	49	"Diseases & Disorders"	"To assess clinical significance, 93 breast cancer lesions were evaluated for expression of VEGF and VEGFR-1 by immunohistochemistry."
"PA"	18630531	0	"Flt-1"	23	28	"Genes & Molecular Sequences"	"breast cancer"	33	46	"Diseases & Disorders"	"Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage."
"PA"	18630531	0	"VEGF"	66	70	"Genes & Molecular Sequences"	"breast cancer"	33	46	"Diseases & Disorders"	"Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage."
"PA"	18630531	6	"VEGF"	0	4	"Genes & Molecular Sequences"	"breast cancer"	48	61	"Diseases & Disorders"	"VEGF was expressed in 60% and VEGFR-1 in 39% of breast cancer specimens."
"PA"	18630531	6	"VEGFR-1"	30	37	"Genes & Molecular Sequences"	"breast cancer"	48	61	"Diseases & Disorders"	"VEGF was expressed in 60% and VEGFR-1 in 39% of breast cancer specimens."
"PA"	18630531	1	"VEGF"	36	40	"Genes & Molecular Sequences"	"breast cancer"	51	64	"Diseases & Disorders"	"Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells."
"PA"	18630531	1	"Flt-1"	203	208	"Genes & Molecular Sequences"	"breast cancer"	51	64	"Diseases & Disorders"	"Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells."
"FA"	19106270	3	"rs11594656"	92	102	"SNP & Sequence variations"	"type 1 diabetes"	138	153	"Diseases & Disorders"	"We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin."
"PA"	19106270	2	"IL2RA"	55	60	"Genes & Molecular Sequences"	"type 1 diabetes"	86	101	"Diseases & Disorders"	"Our objective was to determine whether variants in the IL2RA gene are associated with type 1 diabetes in the Japanese population."
"PA"	19106270	3	"IL2RA"	111	116	"Genes & Molecular Sequences"	"type 1 diabetes"	138	153	"Diseases & Disorders"	"We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin."
"PA"	19106270	8	"IL2RA"	129	134	"Genes & Molecular Sequences"	"type 1 diabetes"	191	206	"Diseases & Disorders"	"The present data confirm the type 1 diabetes association with IL2RA and provide evidence that the different contributions of the IL2RA in the susceptibility to acute-onset and other forms of type 1 diabetes in the Japanese population."
"FA"	19106270	3	"rs3118470"	65	74	"SNP & Sequence variations"	"type 1 diabetes"	138	153	"Diseases & Disorders"	"We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin."
"FA"	19106270	3	"rs706778"	55	63	"SNP & Sequence variations"	"type 1 diabetes"	138	153	"Diseases & Disorders"	"We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin."
"PA"	19106270	5	"rs3118470"	177	186	"SNP & Sequence variations"	"type 1 diabetes"	85	100	"Diseases & Disorders"	"We found evidence of association with acute-onset, but not slow-onset and fulminant, type 1 diabetes for two of the four single-nucleotide polymorphisms genotyped (rs706778 and rs3118470)."
"PA"	19106270	5	"rs706778"	164	172	"SNP & Sequence variations"	"type 1 diabetes"	85	100	"Diseases & Disorders"	"We found evidence of association with acute-onset, but not slow-onset and fulminant, type 1 diabetes for two of the four single-nucleotide polymorphisms genotyped (rs706778 and rs3118470)."
"FA"	19106270	3	"ss52580101"	76	86	"SNP & Sequence variations"	"type 1 diabetes"	138	153	"Diseases & Disorders"	"We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin."
"PA"	17659994	1	"TGFBIp/betaig-h3"	0	16	"Genes & Molecular Sequences"	"adenocarcinoma"	89	103	"Diseases & Disorders"	"TGFBIp/betaig-h3 protein is an extracellular matrix molecule initially cloned from human adenocarcinoma cells treated with TGF-beta."
"PA"	19092998	0	"Cyclophilin A"	46	59	"Genes & Molecular Sequences"	"infection"	104	113	"Diseases & Disorders"	"Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection."
"PA"	19092998	1	"Cyclophilin A"	101	114	"Genes & Molecular Sequences"	"infection"	155	164	"Diseases & Disorders"	"Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 infection and disease progression."
"PA"	19092998	1	"CypA"	116	120	"Genes & Molecular Sequences"	"infection"	155	164	"Diseases & Disorders"	"Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 infection and disease progression."
"FA"	19092998	7	"CypA"	104	108	"Genes & Molecular Sequences"	"infection"	159	168	"Diseases & Disorders"	"The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a weak association with the clinical course of infection in DU."
"FA"	19096231	6	"His1104Asp"	142	152	"SNP & Sequence variations"	"cervical squamous cell carcinoma"	97	129	"Diseases & Disorders"	"Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared to His1104Asp or His1104His genotypes."
"NA"	19096231	8	"XPD Lys751Gln"	37	50	"SNP & Sequence variations"	"cervical carcinoma"	55	73	"Diseases & Disorders"	"No association of XRCC3 Thr241Met or XPD Lys751Gln and cervical carcinoma was found."
"PA"	19096231	2	"XRCC3"	48	53	"Genes & Molecular Sequences"	"carcinogenesis"	137	151	"Diseases & Disorders"	"DNA repair gene polymorphisms, such as those of XRCC3 and xeroderma pigmentosum, complementation group D and G (XPD, XPG), contribute to carcinogenesis."
"PA"	19096231	7	"XPD Asn312Asn"	11	24	"SNP & Sequence variations"	"cervical squamous cell carcinoma"	62	94	"Diseases & Disorders"	"Similarly, XPD Asn312Asn (AA) reduced the risk of cervical or cervical squamous cell carcinoma."
"NA"	19096231	8	"XRCC3 Thr241Met"	18	33	"SNP & Sequence variations"	"cervical carcinoma"	55	73	"Diseases & Disorders"	"No association of XRCC3 Thr241Met or XPD Lys751Gln and cervical carcinoma was found."
"FA"	19096231	6	"His1104His"	156	166	"SNP & Sequence variations"	"cervical squamous cell carcinoma"	97	129	"Diseases & Disorders"	"Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared to His1104Asp or His1104His genotypes."
"PA"	19096231	6	"Asp1104Asp"	26	36	"SNP & Sequence variations"	"cervical squamous cell carcinoma"	97	129	"Diseases & Disorders"	"Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared to His1104Asp or His1104His genotypes."
"PA"	17460184	3	"polymerase gamma"	79	95	"Genes & Molecular Sequences"	"premature aging"	170	185	"Diseases & Disorders"	"Much of this data has been correlative, until recently with the development of polymerase gamma deficient mice which accumulate high levels of mtDNA mutations and show a premature aging phenotype, that a more causative role has been proposed."
"PA"	19092840	2	"TNFSF4 haplotypes"	47	64	"Genes & Molecular Sequences"	"SLE"	159	162	"Diseases & Disorders"	"A recent study demonstrated the association of TNFSF4 haplotypes located in the upstream region with risk for or protection from systemic lupus erythematosus (SLE)."
"PA"	19092840	2	"TNFSF4 haplotypes"	47	64	"Genes & Molecular Sequences"	"systemic lupus erythematosus"	129	157	"Diseases & Disorders"	"A recent study demonstrated the association of TNFSF4 haplotypes located in the upstream region with risk for or protection from systemic lupus erythematosus (SLE)."
"PA"	19092840	4	"TNFSF4"	19	25	"Genes & Molecular Sequences"	"SLE"	31	34	"Diseases & Disorders"	"The association of TNFSF4 with SLE was replicated in all the sets except Spain."
"PA"	19092840	0	"OX40L"	27	32	"Genes & Molecular Sequences"	"systemic lupus erythematosus"	67	95	"Diseases & Disorders"	"Replication of the TNFSF4 (OX40L) promoter region association with systemic lupus erythematosus."
"PA"	19092840	8	"TNFSF4"	101	107	"Genes & Molecular Sequences"	"SLE"	131	134	"Diseases & Disorders"	"This first replication study confirms the association of genetic variation in the upstream region of TNFSF4 with susceptibility to SLE."
"SA"	17123723	9	"NPTN"	27	31	"Genes & Molecular Sequences"	"schizophrenia"	77	90	"Diseases & Disorders"	"These results suggest that NPTN may be involved in genetic susceptibility to schizophrenia."
"PA"	17123723	5	"rs3826047"	59	68	"SNP & Sequence variations"	"schizophrenia"	328	341	"Diseases & Disorders"	"The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia."
"PA"	17123723	5	"rs3840846"	48	57	"SNP & Sequence variations"	"schizophrenia"	328	341	"Diseases & Disorders"	"The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia."
"PA"	17123723	5	"rs3743500"	73	82	"SNP & Sequence variations"	"schizophrenia"	328	341	"Diseases & Disorders"	"The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia."
"PA"	17123723	5	"NPTN"	116	120	"Genes & Molecular Sequences"	"schizophrenia"	328	341	"Diseases & Disorders"	"The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia."
"PA"	17906500	0	"interleukin 22 receptor"	92	115	"Genes & Molecular Sequences"	"Chronic rhinosinusitis with nasal polyps"	0	40	"Diseases & Disorders"	"Chronic rhinosinusitis with nasal polyps is associated with decreased expression of mucosal interleukin 22 receptor."
"PA"	17906500	11	"IL-22R1"	0	7	"Genes & Molecular Sequences"	"CRSsNP"	55	61	"Diseases & Disorders"	"IL-22R1 mRNA was expressed in 100% of the controls and CRSsNP."
"PA"	17906500	12	"IL-22R1"	9	16	"Genes & Molecular Sequences"	"recalcitrant CRSwNP"	60	79	"Diseases & Disorders"	"However, IL-22R1 was only expressed in 55% of patients with recalcitrant CRSwNP."
"SA"	17906500	17	"IL-22R1"	57	64	"Genes & Molecular Sequences"	"CRSwNP"	92	98	"Diseases & Disorders"	"Further research is needed to determine the potential of IL-22R1 as a therapeutic target in CRSwNP."
"FA"	17906500	13	"IL22R1"	24	30	"Genes & Molecular Sequences"	"CRSsNP"	104	110	"Diseases & Disorders"	"Additionally, levels of IL22R1 were significantly lower in recalcitrant CRSwNP compared to controls and CRSsNP."
"PA"	17906500	13	"IL22R1"	24	30	"Genes & Molecular Sequences"	"recalcitrant CRSwNP"	59	78	"Diseases & Disorders"	"Additionally, levels of IL22R1 were significantly lower in recalcitrant CRSwNP compared to controls and CRSsNP."
"SA"	17906500	16	"IL-22R1"	107	114	"Genes & Molecular Sequences"	"CRSwNP"	43	49	"Diseases & Disorders"	"Failure of medical and surgical therapy in CRSwNP is associated with significantly decreased expression of IL-22R1."
"PA"	19110009	3	"Fetuin-A"	0	8	"Genes & Molecular Sequences"	"vascular stiffness"	79	97	"Diseases & Disorders"	"Fetuin-A is a calcification inhibitor and correlates negatively with increased vascular stiffness in dialysis patients."
"PA"	19110009	13	"fetuin-A"	5	13	"Genes & Molecular Sequences"	"aortic stiffness"	60	76	"Diseases & Disorders"	"Male fetuin-A SerSer carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk."
"PA"	19110009	4	"fetuin-A"	4	12	"Genes & Molecular Sequences"	"vascular calcification"	95	117	"Diseases & Disorders"	"The fetuin-A polymorphism (Thr256Ser) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients."
"PA"	19110611	2	"EGFR"	0	4	"Genes & Molecular Sequences"	"pancreatic adenocarcinoma"	24	49	"Diseases & Disorders"	"EGFR gene expression in pancreatic adenocarcinoma cells significantly surpassed that in normal pancreatic cells."
"PA"	19110611	0	"epidermal growth factor"	8	31	"Genes & Molecular Sequences"	"pancreatic carcinoma"	139	159	"Diseases & Disorders"	"Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma."
"PA"	19110611	3	"EGF"	62	65	"Genes & Molecular Sequences"	"pancreatic cancer"	127	144	"Diseases & Disorders"	"On the other hand, AA genome and A allele polymorphism in the EGF gene nucleotide pair G-A 61 is a significant risk factor for pancreatic cancer."
